


Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

| | | |
|---|-----|---|
| 1. Your Name: <i>Kenneth B. Stoller, M.D.</i> | | |
| 2. Your Title: <i>Director, Johns Hopkins Hospital Broadway Center for Addiction</i> | | |
| 3. The Entity(ies) You are Representing: <i>(None. Subject matter expert)</i> | | |
| 4. Are you testifying on behalf of the Federal, or a State or local government entity? | Yes | No <input checked="" type="checkbox"/> |
| 5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed. | | |
| 6. Please attach your curriculum vitae to your completed disclosure form. | | |

Signature: _____



Date: *7/23/18*

CURRICULUM VITAE
The Johns Hopkins University School of Medicine

(Signature) _____
(Typed Name) **Kenneth Stoller, M.D.**

July 9, 2018
(Date of this version)

DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointments

2001-present Assistant Professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
2009-present Director and Medical Director, Johns Hopkins Broadway Center for Addictions
2018-present Interim Medical Director, Addiction Treatment Services at Hopkins Bayview
2009-present Staff Psychiatrist, Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital

Personal Data

Johns Hopkins Broadway Center for Addictions
911 North Broadway
Baltimore, Maryland 21205
410-614-0654 (o)
410-955-4769 (f)
kstolle@jhmi.edu

Education and Training

Undergraduate

1984-1988 B. Sc. (Summa Cum Laude), Zoology (University Honors Program), University of Maryland/College Park, MD

Doctoral/graduate

1988-1992 M.D., Medicine, Johns Hopkins University School of Medicine/Baltimore, MD

Postdoctoral (Internship, residency, fellowship, etc.). *Indicate primary mentors for scholarly activities where applicable*

1992-1993 PGY-I, Internal Medicine/Psychiatry Internship, Johns Hopkins Bayview Medical Center/Baltimore, MD
1993-1996 Residency (PGY-II-IV), Psychiatry, Johns Hopkins Hospital/Baltimore, MD (Specialized rotations including: Short Stay inpatient, Affective Disorders inpatient, Eating Disorders inpatient and day hospital, Sexual Behaviors Consultation Unit, Adolescent Psychiatry inpatient, Psychiatric Day Hospital)
1996-1998 Research and Clinical Fellowship, Johns Hopkins University School of Medicine, Department of Psychiatry (Behavioral Pharmacology Research Unit)/Baltimore, MD (Addiction psychiatry. Research in human psychopharmacology, psychiatric comorbidity, service delivery. Clinical training in addiction treatment)
1995-2005 Non-degree research-related coursework, Johns Hopkins Bloomberg School of Public Health/Baltimore, MD (Biostatistics, cost-effectiveness research, medical economics)

Professional Experience

1993-present Staff Psychiatrist (as resident, fellow, then attending psychiatrist). Johns Hopkins Bayview Medical Center/Baltimore, MD. Provision of psychiatric assessment and treatment in the following settings: Emergency Department, Acute Psychiatric Unit (inpatient), Community Psychiatry Program and consultation liaison psychiatrist to medical and surgical inpatient units. Not currently active other than at ATS program.
1996-1998 Staff Psychiatrist (part-time during fellowship). Addictions Treatment Services at Hopkins Bayview. Johns Hopkins Bayview Medical Center/Baltimore, MD. Perform psychiatric evaluations and initialize treatment for substance abuse patients with comorbid psychiatric presentation. Provide ongoing psychopharmacotherapy and individual psychotherapy, and lead group cognitive-behavioral therapy.
1998-2001 Instructor, Johns Hopkins University School of Medicine/Baltimore, MD, Department of Psychiatry and Behavioral Sciences
1998-2009 Medical Director, Addictions Treatment Services at Hopkins Bayview. Johns Hopkins Bayview Medical Center/Baltimore, MD. Provide clinical and administrative leadership in drug abuse treatment program

- including short term residential, opiate-agonist based long-term ambulatory, short-term ambulatory, and intake/evaluations units.
- 1998-2001 Instructor, Johns Hopkins University School of Medicine/Baltimore, MD. Department of Psychiatry and Behavioral Sciences
- 2001-present Assistant Professor, Johns Hopkins University School of Medicine/Baltimore, MD. Department of Psychiatry and Behavioral Sciences
- 2008-2017 Consultant, acting as Associate Medical Director for Behavioral Health, Johns Hopkins HealthCare, LLC/Baltimore, MD. Provide backup clinical and administrative coverage for the Medical Director. Provide supervision of care management staff on issues involving psychiatric and addictive disorders among members. Served as expert on addictive, psychiatric and pain disorders on numerous quality improvement committees. Participate in research activities.
- 2009-present **(Primary current position)** Director, Medical Director, Johns Hopkins Hospital Broadway Center for Addiction/Baltimore, MD. (Provide clinical and administrative leadership in the Johns Hopkins Hospital outpatient drug abuse treatment center, including standard and intensive outpatient treatment, opiate-agonist based long-term ambulatory treatment, intake/evaluation, and halfway house components)
- 2009-present Attending Psychiatrist, Johns Hopkins Hospital, Department of Psychiatry/Baltimore, MD. Provision of psychiatric assessment and treatment, as well as training to students and residents, on acute psychiatric inpatient units.
- 2018-present Interim Medical Director, Addictions Treatment Services at Hopkins Bayview. Johns Hopkins Bayview Medical Center/Baltimore, MD. Provide clinical and administrative leadership in substance use disorder treatment program including opiate-agonist based long-term ambulatory, short-term ambulatory, specialty program for pregnant women, and intake/evaluation units.

PUBLICATIONS:

Original Research [OR]

1. Brooner R.K., Kidorf M.S., King V.L., **Stoller K.B.** Preliminary evidence of good treatment response in antisocial drug abusers. *Drug and Alcohol Dependence*. 1998; 49(3):249-260. PMID: 9571389.
2. Kidorf M., Brooner R.K., King V.L., **Stoller K.B.**, Wertz J. Predictive validity of cocaine, sedative, and alcohol dependence diagnoses. *Journal of Consulting and Clinical Psychology*. 1998; 66(1): 168-173. PMID: 9489271.
3. King V.L., Brooner R.K., Kidorf M.S., **Stoller K.B.**, Mirsky, A.F. Attention Deficit Hyperactivity Disorder and treatment outcome in opioid abusers entering treatment. *Journal of Nervous and Mental Disease*. 1999; 187(8): 487-495. PMID: 10463066.
4. Mintzer, M.Z., **Stoller, K.B.**, Griffiths, R.R. A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users. *Psychopharmacology*. 1999; 147(2): 200-209. PMID: 10591888.
5. King, V.L., Kidorf, M.S., **Stoller, K.B.**, Brooner, R.K. Influence of psychiatric comorbidity on HIV risk behaviors: Changes during drug abuse treatment. *Journal of Addictive Diseases*. 2000; 19(4): 65-83.
6. Strain, E.C., **Stoller, K.B.**, Walsh, S.L., Bigelow, G.E. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. *Psychopharmacology*. 2000; 148(4): 374-383. PMID: 10928310
7. Carter, J.A., Herbst, J.H., **Stoller, K.B.**, King, V.L., Kidorf, M.S., Costa, P.T., Brooner, R.K. Short-term stability of NEO-PI-R personality trait scores in opioid dependent outpatients. *Psychology of Addictive Behaviors*. 2001;15(3): 255-260. PMID: 11563805.
8. King, V.L., Kidorf, M.S., **Stoller, K.B.**, Carter, J.A., Brooner, R.K. Influence of antisocial personality subtypes on drug abuse treatment response. *Journal of Nervous and Mental Disease*. 2001; 189(9): 593-601.
9. **Stoller, K.B.**, Bigelow, G.E., Walsh, S.L., Strain, E.C. Effects of buprenorphine/naloxone in opioid-dependent humans. *Psychopharmacology*. 2001; 154(3):230-242. PMID: 11351930
10. King, V.L., **Stoller, K.B.**, Hayes, M., Umbricht, A., Curran, M., Kidorf, M.S., Carter, J.A., Schwartz, R., Brooner, R.K. A multicenter randomized evaluation of methadone medical maintenance. *Drug and Alcohol Dependence*. 2002; 65(2):137-148. PMID: 11772475. [SI]
11. Brooner, R.K., Kidorf, M.S., King, V.L., **Stoller, K.B.**, Peirce, J.M., Bigelow, G.E., Kolodner, K. Behavioral contingencies improve counseling attendance in an adaptive treatment model. *Journal of Substance Abuse Treatment*. 2004; 27(3):223-232. PMID: 15501375. [SI]
12. Strain, E.C., Moody, D.E., **Stoller, K.B.**, Walsh, S.L., Bigelow, G.E. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. *Drug and Alcohol Dependence*. 2004; 74(1): 37-43. PMID: 15072805.
13. Kidorf, M.S., King, V.L., Neufeld, K., **Stoller, K.B.**, Peirce, J., Brooner, R.K. Involving significant others in the care of opioid-dependent patients receiving methadone. *Journal of Substance Abuse Treatment*. 2005; 29(1): 19-27. PMID: 15979528. [SI]

14. **Stoller, K.B.**, King, V.L., Clark, M.R., Brooner, R.K. Office-based buprenorphine maintenance: Setting the stage for success. *Advanced Studies in Medicine*. 2006; 6(3):124-134. [PI]
15. **Stoller, K.B.**, King, V.L., Kidorf, M.S., Neufeld, K.S., Brooner, R.K. DSM-III-R versus DSM-IV substance use disorders: Concordance in drug users homogeneous for chronic and severe problems. *Addictive Disorders and Their Treatment*. 2006; 5(4):165-171. DOI 10.1097/01.adt.0000210077.92111.bf
16. King, V.L., **Stoller, K.B.**, Kidorf, M.S., Kolodner, K., Schwartz, R.P., Brooner, R.K. A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. *Journal of Substance Abuse Treatment*. 2006; 31(4): 385-393. PMID: 17084792. [SI]
17. Brooner, R.K., Kidorf, M.S., King, V.L., **Stoller, K.B.**, Neufeld, K.J., Kolodner, K. Comparing adaptive stepped care and monetary-based voucher interventions for opioid dependence. *Drug and Alcohol Dependence*. 2007; 88(Suppl 2):S14-23. PMID: 17257782. [SI]
18. Clark, M.R., **Stoller, K.B.**, Brooner, R.K. Assessment and management of chronic pain in individuals seeking treatment for opioid dependence disorder. *Canadian Journal of Psychiatry*. 2008; 53(8):496-508. PMID: 18801211. [PI]
19. King, V.L., **Stoller, K.B.**, Neufeld, K.S., Peirce, J.M., Kidorf, M.S., Clark, M.R. Brooner, R.K. Implementing methadone medical maintenance in community-based clinics: Disseminating evidence based treatment. *Journal of Substance Abuse Treatment*. 2008; 35(3): 312–321. PMID: 18294805. [SI]
20. Burke, C.K., Peirce, J.M., Kidorf, M.S., Neubauer, D., Punjabi, N.M., **Stoller, K.B.**, Hursh, S., Brooner, R.K. Sleep problems reported by patients entering opioid agonist treatment. *Journal of Substance Abuse Treatment*. 2008; 35(3):328-33. PMID: 18248944.
21. King, V.L., **Stoller, K.B.**, Kidorf, M., Kindbom, K., Hursh, S., Brady, T., Brooner, R.K. Assessing the effectiveness of an internet-based videoconferencing platform for delivering intensified substance abuse counseling. *Journal of Substance Abuse Treatment*. 2008; 36(3):331-338. PMID: 18775625. [SI]
22. Peirce, J.M., **Burke, C.K.**, **Stoller, K.B.**, Neufeld, K.J., Brooner, R.K. Assessing traumatic event exposure: comparing the Traumatic Life Events Questionnaire to the Structured Clinical Interview for DSM-IV. *Psychological Assessment*. 2009; 21(2):210-8. PMID: 19485675.
23. Neufeld, K., Kidorf, M., King, V., **Stoller, K.**, Clark, M., Peirce, J., Brooner, R.K. Using enhanced and integrated services to improve response to standard methadone treatment: Changing the clinical infrastructure of treatment networks. *Journal of Substance Abuse Treatment*. 2010; 38(2):170-7. PMID: 19717272. [SI]
24. Brooner, R.K., Kidorf, M.S., King, V.L., Peirce, J., Neufeld, K., **Stoller, K.**, Kolodner, K. Managing psychiatric comorbidity within versus outside of methadone treatment settings: A randomized and controlled evaluation. *Addiction*. 2013; 108(11):1942-51. PMID: 23734943. [SI]
25. McClure, E.A., **Acquavita, S.P.**, Dunn, K.E., **Stoller, K.B.**, Stitzer, M.L. Characterizing smoking, cessation services, and quit interest across outpatient substance abuse treatment modalities. *Journal of Substance Abuse Treatment*. 2014; 46(2):194-201. PMID: 23988192.
26. **Saloner, B.**, **Stoller, K.B.**, Barry, C.L. Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment. *Psychiatric Services*. 2016; 67(6):676-9. PMID: 26927578.
27. Cantor, J., **Stoller, K.B.**, **Saloner, B.** The response of substance use disorder treatment providers to changes in macroeconomic conditions. *Journal of Substance Abuse Treatment*. 2017. 81:59-65. PMID: 28847456.
28. **Saloner, B.**, **Stoller, K.B.**, Alexander, C. Moving Care to the Mainstream: Improving Buprenorphine Treatment Quality. *New England Journal of Medicine*. *New England Journal of Medicine*. 2018. 379(1):4-6. PMID: 29972745

Book Chapters, Monographs [BC]

1. Strain, E.C., **Stoller, K.B.** Introduction and Historical Overview. In: Strain, E.C. and Stitzer, M.L. (Eds.) *Methadone Treatment for Opioid Dependence*. Baltimore: The Johns Hopkins University Press, 1999.
2. **Stoller, K.B.**, Bigelow, G.E. Regulatory, Cost and Policy Issues. In: Strain, E.C. and Stitzer, M.L. (Eds.) *Methadone Treatment for Opioid Dependence*. Baltimore: The Johns Hopkins University Press, 1999.
3. **Stoller, K.B.**, Stitzer, M.L., Brooner, R.K., King, V.L., Kidorf, M.S. Smoking cessation program in an opioid substitution clinic. Published abstract in *Nicotine & Tobacco Research*. 1999; 1:95-113.
4. **Stoller, K.B.**, **Carter, J.A.**, King, V.L., Kidorf, M.S., Brooner, R.K. Behaviorally contingent pharmacotherapy in the treatment of opioid dependent patients on LAAM. In *Drug and Alcohol Dependence*. 2000; 60(Suppl 1):S214. DOI: 10.1016/S0376-8716(00)90000-0 [SI]
5. **Carter, J.A.**, King, V.L., Kidorf, M.S., **Stoller, K.B.**, & Brooner, R.K. Effects of Behaviorally Contingent Pharmacotherapy on treatment outcome of opioid dependent outpatients. In *Drug and Alcohol Dependence*. 2000; 60(Suppl 1):S33. DOI: 10.1016/S0376-8716(00)90000-0 [SI]
6. **Stoller, K.**, Kidorf, M., King, V., **Carter, J.**, Brooner, R. Characteristics of drug treatment patients with versus without medical assistance. In *Drug and Alcohol Dependence*. 2001; 63(Suppl 1):S152.

7. King, V.L., Kidorf, M.S., **Stoller, K.B.**, Carter, J.A., Brooner, R.K. Influence of antisocial personality subtypes on drug abuse treatment response. In *Drug and Alcohol Dependence*. 2001; 63(Suppl 1):S81.
8. Carter, J., Kidorf, M., **Stoller, K.**, King, V., Brooner, R. Cross-sectional comparison of opioid- and cocaine-dependent individuals with and without physiological dependence to cocaine. In *Drug and Alcohol Dependence*. 2002; 66(Suppl 1):S24.
9. King, V., Brooner, R., Kidorf, M., **Stoller, K.**, Carter, J., Schwartz, R. A controlled trial of methadone medical maintenance: 12-month results. In *Drug and Alcohol Dependence*. 2002; 66(Suppl 1):S94. [SI]
10. Strain, E.C., Moody D.E., **Stoller, K.**, Walsh, S.L., Bigelow, G.E. Bioavailability of buprenorphine solution versus tablets during chronic dosing in opioid-dependent subjects. In *Drug and Alcohol Dependence*. 2002; 66(Suppl 1):S176.
11. **Stoller, K.B.**, Carter, J.A., King, V.L., Kidorf, M.S., Brooner, R.K. Early treatment response to a “Motivated Stepped Care” approach using LAAM: Comparison with methadone study. In *American Journal on Addictions*. 2003; 12(3):277-278.
12. **Stoller, K.B.**, Bigelow, G.E. Introduction and Historical Overview. In: Strain, E.C. and Stitzer, M.L. (Eds.) The Treatment of Opioid Dependence. Baltimore: The Johns Hopkins University Press, 2006.
13. **Stoller, K.B.**, Bigelow, G.E. Regulatory, Cost and Policy Issues. In: Strain, E.C. and Stitzer, M.L. (Eds.) The Treatment of Opioid Dependence. Baltimore: The Johns Hopkins University Press, 2006.
14. King, V.L., **Stoller, K.B.**, Kidorf, M, Neufeld, K.J., Peirce, J, Brooner, R.K. Translating Efficacy to Effectiveness in Opioid Dependence Treatment, in Angela Browne-Miller, (Ed.), The Praeger International Collection on Addictions. Westport, CT: Praeger-Greenwood Publishing Group, 2009.
15. Brooner, R.K., Disney, E.R., Neufeld, K.S., King, V.L., Kidorf, M., **Stoller, K.B.** Antisocial Personality Disorder in Patients with Substance Use Disorders. In: Nunes, E.V., Selzer, J., Levounis, P., and Davies, B.S., (Eds.), Substance Dependence and Co-Occurring Psychiatric Disorders: Best Practices for Diagnosis and Clinical Treatment. Kingston, NJ: Civic Research Institute, 2010.
16. **Stoller, K.B.** A collaborative opioid prescribing (CoOP) model linking opioid treatment programs with office-based buprenorphine providers. In *Addiction Science & Clinical Practice*. 2015; 10(Suppl 1):A63. [SI]
17. Disney, E. **Stoller, K.B.**, Vandrey, R. Synthetic cannabinoid use and awareness in a drug abuse treatment clinic. In *Drug & Alcohol Dependence*. 2015; 146, e267-e268.
18. Strain, E.C., **Stoller, K.B.** Buprenorphine Maintenance. In: Galanter, M., Kleber, H.D., Brady, K.T., (Eds.), The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 5th Edition. Arlington, VA: American Psychiatric Publishing, Inc., 2015.
19. **Stoller, K.B.** Psychiatric Co-occurring Disorders. In: Rastegar, D. & Fingerhood M., (Eds.), The American Society of Addiction Medicine Addiction Medicine Handbook. New York, NY. Oxford University Press, 2015. ISBN/ISSN: 9780190214647

Other Publications:

Proceedings Reports [PR]

1. **Stoller, K.B.**, Brooner, R.K., King, V.L., Kidorf, M.S. Comparison of opioid abusers with independent versus substance-induced major depression. In: *Problems of Drug Dependence 1997: Proceedings of the 59th Annual Scientific Meeting of The College on Problems of Drug Dependence, Inc.*, National Institute on Drug Abuse Research Monograph 178, DHHS, Bethesda, MD: National Institutes of Health, 1998, pg. 254.
2. Kidorf, M.S., Brooner, R.K., King, V.L., **Stoller, K.B.**, Wertz, J. Predictive validity of substance dependence diagnoses. In: *Problems of Drug Dependence 1997: Proceedings of the 59th Annual Scientific Meeting of The College on Problems of Drug Dependence, Inc.*, National Institute on Drug Abuse Research Monograph 178, DHHS, Bethesda, MD: National Institutes of Health, 1998, pg. 321.
3. Wertz, J., Brooner, R.K., Kidorf, M.S., King, V.L., **Stoller, K.B.** Effects of personality on treatment compliance and drug use in methadone patients. In: *Problems of Drug Dependence 1997: Proceedings of the 59th Annual Scientific Meeting of The College on Problems of Drug Dependence, Inc.*, National Institute on Drug Abuse Research Monograph 178, DHHS, Bethesda, MD: National Institutes of Health, 1998, pg. 327.
4. **Stoller, K.B.**, Strain, E.C., Bigelow, G.E. Buprenorphine/naloxone combination tablet: effects in opioid-dependent volunteers. In: Harris, LS (ed), *Problems of Drug Dependence 1998: Proceedings of the 60th Annual Scientific Meeting of The College on Problems of Drug Dependence, Inc.*, National Institute on Drug Abuse Research Monograph 179, DHHS, Bethesda, MD: National Institutes of Health, 1999, pg. 230.
5. King, V.L., Brooner, R.K., Kidorf, M.S., **Stoller, K.B.** Comparison of Substance Use Diagnoses Using DSM-III-R vs. DSM-IV in outpatient drug abusers. In: Harris, LS (ed), *Problems of Drug Dependence 1998: Proceedings of the 60th Annual Scientific Meeting of The College on Problems of Drug Dependence, Inc.*, National Institute on Drug Abuse Research Monograph 179, DHHS, Bethesda, MD: National Institutes of Health, 1999, pg. 287.

6. Strain, E.C., **Stoller, K.B.**, Walsh, S.L., Bigelow, G.E. Buprenorphine/naloxone combination tablet: effects in non-dependent opioid abusers. In: Harris, LS (ed), Problems of Drug Dependence 1998: Proceedings of the 60th Annual Scientific Meeting of The College on Problems of Drug Dependence, Inc., National Institute on Drug Abuse Research Monograph 179, DHHS, Bethesda, MD: National Institutes of Health, 1999, pg. 102.
7. Kidorf, M.S., Brooner, R.K., King, V.L., **Stoller, K.B.** Antisocial personality disorder and treatment outcome in opioid dependent outpatients. In: Harris, LS (ed), Problems of Drug Dependence 1998: Proceedings of the 60th Annual Scientific Meeting of The College on Problems of Drug Dependence, Inc., National Institute on Drug Abuse Research Monograph 179, DHHS, Bethesda, MD: National Institutes of Health, 1999, pg. 50.
8. Mintzer, M.Z., **Stoller, K.B.**, Griffiths, R.R. Flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users. In: Harris, LS (ed), Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting of The College on Problems of Drug Dependence, Inc., National Institute on Drug Abuse Research Monograph 180, DHHS, Bethesda, MD: National Institutes of Health, 2000, pg. 182.
9. **Stoller, K.B.**, Brooner, R.K., Kidorf, M.S., King, V.L., Carter, J.A. Characterization of opioid substitution patients referred from needle exchange. In: Harris, LS (ed), Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting of The College on Problems of Drug Dependence, Inc., National Institute on Drug Abuse Research Monograph 180, DHHS, Bethesda, MD: National Institutes of Health, 2000, pg. 326.
10. Carter, J.A., Herbst, J.H., **Stoller, K.B.**, King, V.L., Costa, P.T., Brooner, R.K. Stability and factor structure of NEO-PI-R scores of opioid dependent patients. In: Harris, LS (ed), Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting of The College on Problems of Drug Dependence, Inc., National Institute on Drug Abuse Research Monograph 180, DHHS, Bethesda, MD: National Institutes of Health, 2000, pg. 133.
11. King, V.L., Brooner, R.K., **Stoller, K.B.**, Gandhi, D., Schwartz, R., Hayes, M. Preliminary findings from a controlled trial of methadone medical maintenance. In: Harris, LS (ed), Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting of The College on Problems of Drug Dependence, Inc., National Institute on Drug Abuse Research Monograph 180, DHHS, Bethesda, MD: National Institutes of Health, 2000, pg. 157. [SI]

Guidelines/Protocols, Consensus Statement, Expert Opinion, Consortium Articles [GL]

1. Kauffman, J., **Stoller, K.B.**, Stavros, G., McCarroll, B., Linzy, S. “*Guidelines for addressing benzodiazepine use in Opioid Treatment Programs.*” <http://www.aatod.org/guidelines-for-addressing-benzodiazepine-use-in-opioid-treatment-programs-otps/>. Published online April 6, 2017.

Editorials [ED]

1. **Stoller, K.B.** “Maryland prisons need a more enlightened approach to drug treatment.” The Baltimore Sun. July 22, 2016. Print, and published online <http://www.baltimoresun.com/news/opinion/readersrespond/bs-ed-prison-mail-letter-20160722-story.html>

Research Letters/White Papers/Brief Reports [RL]

1. (*White paper commissioned by the U.S. Substance Abuse and Mental Health Services Administration*): **Stoller, K.B.**, Stephens, M.C., Schorr, A. Integrated Service Delivery Models for Opioid Treatment Programs in an Era of Increasing Opioid Addiction, Health Reform, and Parity. Substance Abuse and Mental Health Administration. <http://www.aatod.org/policies/mat-hub-setting-whitepapers/> Published online July 13, 2016. [SI]

Media Releases or Interviews [MR]

1. (Interview, subject of article) Botticelli, M. “Addressing the Prescription Opioid and Heroin Crisis.” ATTC Messenger. September 2015; <http://www.attcnetwork.org/Botticelli%20-%20MAT%20Article%20for%20ATTC%20Messenger%2020150819%20COS%20Approved%20v3.pdf>
2. (Interview, subject of article) Knopf, A. “OTPs Can Help Support Primary Care Buprenorphine Prescribers.” Addiction Treatment Forum. August/September 2015. 26(5). <http://atforum.com/2015/10/otps-can-help-support-primary-care-buprenorphine-prescribers/>
3. (Televised interview) “Episode 1903: Prescription Drug Addiction Roundtable Part I.” This Is America & The World. Public Broadcasting System. Initial air date 10/16/2015. Televised and online at http://www.thisisamerica.net/include/include-tia_1903.html?keepThis=true&TB_iframe=true&height=316&width=560, <https://youtu.be/jQEeFumlVgY>
4. (Televised interview) “Episode 1904: Prescription Drug Addiction Roundtable Part II.” This Is America & The World. Public Broadcasting System. Initial air date 10/23/2015. Televised and online at http://www.thisisamerica.net/videoarchive_2015-2016.html, <https://youtu.be/LCGaj4kl5KU>

5. (Televised interview) "Prescription Drug Addiction:1 Hour Special." This Is America & The World. Public Broadcasting System. Initial air date 10/23/2015. Televised and online at <https://youtu.be/UpESjEr-XE>
6. (Interview, subject of article) Vestal, C. "An Opioid Treatment Model Spawns Imitators." Stateline (The Pew Charitable Trusts, Research and Analysis). April 27, 2016. <http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2016/04/27/an-opioid-treatment-model-spawns-imitators>. Also published by Huffington Post, Baltimore Sun, Chicago Tribune, Los Angeles Times, Partnership for Drug-Free Kids, Providence Journal, Texarkana Gazette. [SI]
7. (Interview, subject of article) Minkove, J.F. "A Medical Model to Treat Opioid Addiction – And Link Care." Brainwise, Fall 2016. Johns Hopkins Medicine. <http://www.hopkinsmedicine.org/news/articles/a-medical-model-to-treat-opioid-addiction-and-link-care>
8. (Interview) Scharper, J. "Administered for pain, drugs like OxyContin have taken a massive toll." Johns Hopkins Magazine, Fall 2016. <http://hub.jhu.edu/magazine/2016/fall/opioid-addiction-pain-management/>
9. (Radio interview) Kast, S. & Harvie, M. "Can Medication Stop the Opioid Epidemic?" WYPR national public radio, aired 11/15/16. <http://wypr.org/post/can-medication-stop-opioid-epidemic>. (Associated patient interview at <http://wypr.org/post/personal-story-addiction-and-recovery>)
10. (Interview) "The opioid crisis: Part 1, Understanding brain chemistry important to breaking addiction, experts say." WBAL TV, Baltimore. Aired 11/23/2016. <http://www.wbal.com/article/understanding-brain-chemistry-important-to-breaking-addiction-experts-say/8356982>
11. (Subject of article) Knopf, A. "How OTPs Can Integrate Care with Other Health Care Providers." Addiction Treatment Forum. December 6, 2016. <http://atforum.com/2016/12/how-otps-integrate-care-health-care-providers/>
12. (Interview) "The opioid crisis: Part 2, Treatment can help turn around opioid abuse." WBAL TV, Baltimore. Aired 1/30/2017. <http://www.wbal.com/article/understanding-brain-chemistry-important-to-breaking-addiction-experts-say/8356982>
13. (Radio interview and online news article) "When addiction treatment means decades on Methadone" National Public Radio, WYPR. Aired 8/3/2017.
Online story: <http://wypr.org/post/when-addiction-treatment-means-decades-methadone> .
Audio: https://cpa.ds.npr.org/wyprmain/audio/2017/08/WYPRNEWS_RBAYE_OPIOIDS_080317.mp3
14. (Podcast) "Treating Opioid Addiction." The American Health Podcast. Aired 1/10/2018.
<http://americanhealth.libsyn.com/treating-opioid-addiction>

FUNDING

EXTRAMURAL Funding

Research Extramural Funding - Grants or contracts obtained to support a research initiative

- | | |
|-----------|---|
| 1998-2003 | Treatment Research Center: Behavioral Pharmacology P50 DA-05273 NIH/NIDA \$11,091,438 total direct cost PI: G. Bigelow Role: Component co-principal investigator, 20% effort Notes: Central theme was treatment comparisons. This component evaluated the efficacy of Motivational Stepped Care (MSC) using both methadone and LAAM pharmacotherapies |
| 1998-2003 | Comparing Complementary Behavior Therapies RO1 DA 12049 NIH/NIDA \$1,783,323 direct cost PI: R. Brooner Role: Co-investigator, 20% effort Notes: Study evaluated the effect of combinations of contingent voucher reinforcement and an adaptive stepped care model in patients on methadone maintenance. |
| 1999-2001 | A controlled clinical trial of methadone medical maintenance Open Society Institute-Soros Foundation \$185,751 direct cost PI: V. King |

Role: Co-investigator, 10% effort

Notes: This study randomized patients to receive methadone medical maintenance within community physician offices, methadone medical maintenance within the treatment clinic, or standard treatment, and evaluated adherence and outcome.

- 2002-2005 Increasing Interest and Use of Methadone Medical Maintenance Interventions in Community Treatment Programs
Open Society Institute and Baltimore Substance Abuse Systems, Inc
\$176,913 direct costs
PI: V. King
Role: Co-investigator, recent effort covered under K23 DA 16250-01
Notes: This project systematically documented the various methods employed by five treatment programs in Baltimore to implement and monitor methadone medical maintenance interventions.
- 2003-2006 Measuring the Enhancement of Integrated Care Management for a Medicaid Population with Substance Abuse and High Medical Expenses: is there a positive return on investment?
Grant 100187
Center for Health Care Strategies (CHCS)
\$45,872 direct cost
PI: P. Fagan
Role: Co-investigator and medical director, effort under K23 DA 16250-01
Notes: Component of a multi-site demonstration on the business case for quality; study examined the effect of integrating somatic and substance use disorder care management in Medicaid-MCO members with substance use and high costs.
- 2003-2008 Cost and Adherence in Drug Abuse Treatment
K23 DA 16250-01
NIH/NIDA
\$821,157 total direct cost
PI: K. Stoller
Role: Principal Investigator, 80% salary support
Notes: This grant was a Mentored Patient-Oriented Research Career Development Award, with work focusing on patient adherence and cost benefit as they relate to substance abuse treatment. The primary investigations evaluate the cost and cost-benefit of drug abuse treatment services and both interventions and service models designed to improve patient adherence. Two studies evaluate cost and cost-benefit of a Motivated Stepped Care (MSC) treatment system for patients receiving either methadone or LAAM. The third study compares treatment costs and cost-benefit for combinations of MSC and voucher-based incentive to reduce drug use. Other studies systematically evaluate the relationships between substance use problems, overall and specific medical service utilization and costs, and receipt of substance abuse treatment, using data from a Medicaid managed care organization.
- 2003-2009 Services Research: Psychiatric Comorbidity in Drug Abusers
R01-DA016375
NIH/NIDA
\$2,692,866 total direct cost
PI: R. Brooner
Role: Co-investigator, 5% effort
Notes: Determined the effect of treatment setting (integrated into comprehensive drug abuse treatment program vs. referred to community psychiatric clinic) on psychiatric and drug abuse treatment outcomes in opioid-dependent patients with co-occurring drug abuse and other psychiatric disorders.
- 2005-2007 Structuring the Integration of Services For Medicaid Recipients With Chronic Illness and Psychiatric and/or Substance Abuse Problems
Grant 100326
Center for Health Care Strategies (CHCS)
\$45,871 direct cost
PI: P. Fagan

Role: Co-investigator and medical director, effort under K23 DA 16250-01
Notes: Component of a multi-site demonstration on the business case for quality; study examined the effect of integrating somatic and substance use disorder care management while coordinating care with the mental health carve-out in a sample of Medicaid-MCO members with substance use problems and high medical costs.

- 2005-2010 Employment-Based Addiction Pharmacotherapy
R01-DA193861
NIH/NIDA
\$2,535,220 total direct cost
PI: K. Silverman
Role: Co-investigator. 5% effort covered under K23 DA 16250-01
Notes: This grant evaluates the effect of integrating naltrexone therapy into the therapeutic workplace intervention
- 2007-2010 Comprehensive Disease Management Program for Medically Complex Substance Users
NA_00012278
Johns Hopkins HealthCare, L.L.C.
\$229,054 total direct cost
PI: J.H. Young
Role: Co-investigator.
Notes: Evaluation of embedded care management and contingency management to improve medical adherence and reduce costs among Medicaid recipients with substance abuse
- 2015-present The National Drug Abuse Treatment Clinical Trials Network (CTN)
Mid Atlantic node
NIH grant UG1DA013034-16
Co-PI's: M. Stitzer and R. Schwartz
Role: Affiliated Faculty Investigator
Notes: The CTN conducts multi-site trials testing the efficacy and effectiveness of new treatments- pharmacological and behavioral- for substance use disorders.
- 2015-2018 Social Network Intervention for Syringe Exchange Registrants
R34-DA040507-01
NIH-NIDA
\$250,000 first year direct cost
P.I. M. Kidorf
Supplemental Award (2017 – 2018)
 Using community pharmacies to dispense methadone to expand treatment settings for opioid use disorder
 PI: R.K. Brooner
 \$98,300 first year direct cost
Role: Co-Investigator

Educational Extramural Funding – Grants or contracts obtained to support an educational initiative, incl. training grants

- 2018-2019 Johns Hopkins Substance Use Problem Education and Resource Initiative
Funded through Laurie Lundy and The Lundy Family Foundation
\$150,000
Role: Faculty Lead
Notes: Funding is to plan for the creation of a new and unique institute to address the national substance abuse problem, including to plan for a new and sustained academic education institute at Johns Hopkins that will aim to improve professional and public knowledge about substance use disorders; broadly increase the awareness of evidence-based treatments; and, reduce the stigma associated with these conditions.

Clinical Extramural Funding - Grants or contracts obtained to support a clinical initiative

- 1997-2009 Ambulatory Service Grant, Addiction Treatment Services
Grant Number 1A 243172 AB.
State of Maryland, Alcohol and Drug Abuse Administration and Baltimore Substance Abuse Services, Inc.
ATS at Hopkins Bayview
FY08 budget approximately \$3,300,000, cumulative revenue approximately \$43,100,00 (1994 – 2009).
Role: Associate Medical Director
- 1997-1999 Needle Exchange Treatment Initiative
Baltimore City Health Department
ATS at Hopkins Bayview
Budget: \$178,000, cumulative revenue \$715,000 (1994 – 1999).
Role: Medical Director- Addiction Treatment Services, MFL
- 1997-2006 Block grant funding for residential intermediate care facility unit
State of Maryland, Alcohol and Drug Abuse Administration and Baltimore Substance Abuse Services, Inc.
16 beds at ATS-MFL at Hopkins Bayview
Role: Associate Medical Director
- 2000-2006 Treatment Enhancement Initiative
State of Maryland, Alcohol and Drug Abuse Administration and Baltimore Substance Abuse Services, Inc.
ATS-BBRC at Hopkins Bayview.
- 2006-2010 Special Initiative: CAST (Community Access to Specialized Treatment)
Grant Number 1A 24 317 2AB,
State of Maryland, Alcohol and Drug Abuse Administration and Baltimore Substance Abuse Services, Inc.
ATS at Hopkins Bayview
FY07 budget: \$500,000 total cost.
- 2009-2010 HIDTA: Johns Hopkins Hospital Comprehensive Women’s Center Halfway House/Buprethorphone
10-102-5415-000
Office of National Drug Control Policy: High Intensity Drug Trafficking Areas (HIDTA) and Baltimore Substance Abuse Services, Inc.
Budget: \$110,850
Role: Principal Investigator, Director
- 2009-2010 Ambulatory Service Grant, Medication Assisted Treatment
10-02-5414.
State of Maryland, Alcohol and Drug Abuse Administration and Baltimore Substance Abuse Services, Inc.
Budget: \$3,566,026
Role: Associate Medical Director
- 2009-present Johns Hopkins Hospital Broadway Center - Outpatient (OP) & Intensive Outpatient (IOP)
Substance Use Treatment Services
AS019-OPIOP-JHH
State of Maryland, Behavioral Health Administration and Behavioral Health System Baltimore.
FY 2019 Award: \$137,217
Role: Director
- 2009-present Johns Hopkins Hospital - Wilson House Residential Service – Clinically Managed Low Intensity
Treatment Level 3.1
AS019-3.1-JHH
State of Maryland, Behavioral Health Administration and Behavioral Health System Baltimore.
FY 2019 Award: \$123,953
Role: Director

2016-present Johns Hopkins Hospital - Recovery Support/Peer Services
AS278-RSSE-JHHB
Behavioral Health System Baltimore.
FY 2019 Award: \$28,778
Role: Director

System Innovation or Quality Improvement Extramural Funding - Grants or contracts obtained to support an initiative

- 2004-2005 Improving inpatient psychiatric payment: cost and quality implications
1R01-MH079293-01A1
NIH/NIMH
\$1,259,616
PI: D. Steinwachs
Role: Consultant
Notes: Project seeks to improve DRG classifications for psychiatric admissions to provide efficiency incentives for inpatient mental health care.
- 2008-2009 Improving Inpatient Psychiatric Payment: Cost and Quality Implications
R01-MH079293-01A1
NIH/NIMH
\$1,486,067 total direct cost
PI: D. Steinwachs
Role: Consultant
Notes: This project brought together experts in psychiatric treatment, statistics, and health services to improve the system of reimbursement for inpatient psychiatric treatment, using demographic and clinical data from claims and record abstraction.
- 2011-2012 Improving Behavioral Health Data Contributions to the ACG Predictive Modeling System™
Johns Hopkins HealthCare, LLC
Effort covered under \$30,000 annual salary supplement from JHHC
Project Co-Leads: David Bodycombe, Klaus Lemke, Ph.D, Peter J. Fagan, Ph.D,
Role: Co-investigator
Notes: The project seeks to improve the predictive validity of the ACG system™ regarding the algorithmic use of mental health and substance abuse diagnoses and other psychosocial data that are available to health plans. The goal is to be able to have more reliable and valid measures of morbidity risk and healthcare services utilization in populations.
- 2014 Providers' Clinical Support System (PCSS-MAT) "minigrant": Collaborative Opioid Prescribing, a National Quality Improvement Pilot
Funded by American Academy of Addiction Psychiatry to the American Association for the Treatment of Opioid Dependence
\$5,000 total direct cost
PI: K. Stoller, M.D.
Role: PI. Support only for travel to present at meetings
Notes: Awarded grant as AATOD's Board Member and Representative to PCSS/AAAP Steering Committee. Facilitate and evaluate implementation of coordinated care models through 25 opioid treatment programs nationwide.
- 2018 Providers' Clinical Support System "minigrant": Telemedicine in Opioid Treatment Programs.
Funded by American Academy of Addiction Psychiatry to the American Association for the Treatment of Opioid Dependence
\$5,000 total direct cost (Stoller funding to support presentations/travel)
PI: K. Stoller, M.D.
Role: PI. Support only for travel to present at meetings
Notes: Awarded grant as AATOD's Board Member and Representative to PCSS/AAAP Steering Committee. Develop document identifying key approaches in how OTP patients can benefit from the use of telemedicine services, especially in rural and underserved parts of the United States.

Working with AATOD, American Telemedicine Association, SAMHSA, DEA and AAAP to develop basic guidance.

CLINICAL ACTIVITIES

Medical, other state/government licensure

1995-present Medical License, State of Maryland (D0047266)

2013-present Licensed Clinical Alcohol and Drug Approved Supervisor, Maryland Board of Professional Counselors and Therapists (Ref# 608)

Boards, other specialty certification

1998-2018 Diplomat in the Specialty of Psychiatry by the American Board of Neurology and Psychiatry (No. 45413)

2003-present. "Qualifying physician" permitted to prescribe buprenorphine for the treatment of opioid dependence with additional permission (since 2007) to treat up to 100 patients.

2018-2027 Certified in Addiction Medicine by the American Board of Preventative Medicine (Certification number: 61-3304)

Clinical (Service) Responsibilities

- 1998-2009. Medical Director. Addiction Treatment Services (ATS) at Hopkins Bayview (including OTP component). Responsible for addiction treatment clinic, including a 16-bed residential program (approx. 800 admissions per year; closed in 2006), a 240 patient ambulatory component, and the evaluations and admissions unit through which all ATS patients are admitted to MFL and BBRC sites. Treatment consisting of any of the following: short-term residential rehabilitation with or without medical detoxification, short-term ambulatory treatment with or without medical detoxification, and long-term ambulatory treatment typically utilizing methadone or LAAM agonist therapy. Range of duties includes:
- Conduct daily multidisciplinary rounds - new admissions are reviewed and treatment planning takes place. Treatment approach utilizes primarily pharmacotherapy, cognitive-behavioral therapies, and treatment contingencies. Consult with clinic nursing and counseling staff, as well as doctoral staff both in regular supervision and as needed to discuss current patient issues.
 - Directly supervise senior and first-line clinical staff such as Associate Director, Patient Care Manager, Substance Abuse Program Coordinator, Intake counselors. Also provided direct supervision to select administrative staff, including Administrative Director.
 - Conduct cognitive-behavioral group therapy sessions as well as weekly Treatment Re-evaluation team meetings, which are attended primarily by patients without optimal response to treatment.
 - Conduct psychiatric evaluation for residential and ambulatory patients exhibiting or reporting psychiatric symptoms. Provide ongoing psychotherapy and psychopharmacotherapy for ATS patients with comorbid non-substance psychiatric illness.
 - Conduct teaching rounds to provide training to ATS staff regarding such issues as motivational enhancement, assessment and treatment of psychiatric comorbidity, and treating patients with personality vulnerabilities.
 - Provide 24 hours per day / 7 days per week pager coverage to ATS for administrative and clinical issues.
 - Trained psychiatric interns and residents regarding the evaluation of individuals with addictions in the Emergency Department, and ATS coverage protocols.
 - Attend Senior Staff and Executive Staff meetings at ATS, as well as select Bayview Medical Center meetings such as the Psychiatry Joint Practice Committee and JCAHO focus groups.
 - Integrally involved in the overall clinical, organizational, administrative, and fiscal operation and planning for ATS. This includes hiring of staff, preparation of service grant applications, preparation of program budgets, assisting in the monitoring and forecasting of expenses, meeting with hospital administration as needed, and regularly meeting with representatives of managed care organizations and the public service grant agencies that supply funding to ATS.
 - Track data regarding patient treatment and program targets on an ongoing basis. Data is used to report to psychiatry department, funding agencies and accreditation bodies, as well as to assist in the design and monitoring of performance improvement initiatives.
- 1998-2009. Staff Psychiatrist, Johns Hopkins Bayview Medical Center.

- a) Attending Psychiatrist (until 2009) on the inpatient 20-bed Acute Psychiatric Unit (inpatient) approximately one month per year. Responsible for the management of psychiatric inpatients one month per year. Lead multidisciplinary team rounds, conduct electroconvulsive therapy (until 2003), and supervise psychiatric residents and medical students.
- b) Attending Psychiatrist (until 2008) performing psychiatric consultation for the acute hospital (medical, surgical, obstetrics, pediatrics services), approximately 2 weeks per year.
- 2008-2017 Assistant to the Medical Director of Behavioral Health, Johns Hopkins HealthCare, LLC. Provide backup clinical and administrative coverage for the Medical Director. Provide supervision of care management supervisory and line staff on issues involving psychiatric and addictive disorders among members. Serves as expert resource on addictive, psychiatric and pain disorders on numerous quality improvement committees. QI project involvement includes those related to recognizing and treating depression in primary care, quality in intensive outpatient programs for addiction, use of buprenorphine pharmacotherapy, and opiate dependence and chronic pain disorders. Develop and participate in research activities relating to addiction and mental illness among members of the JHHC insurance lines.
- 2009-present Director, Johns Hopkins Hospital Broadway Center for Addictions. Provide clinical and administrative leadership in the Johns Hopkins Hospital outpatient drug abuse treatment center, including standard and intensive outpatient treatment, opiate-agonist based long-term ambulatory treatment, intake/evaluation, and halfway house components. Range of duties includes:
- a) Directly responsible for overall clinical, organizational, administrative, and fiscal operation and planning for the Broadway Center. This includes hiring of staff, preparation of service grant applications, preparation of program budgets, monitoring and forecasting of expenses, meeting with hospital administration, identifying new sources of revenue, and regularly meeting with representatives of managed care organizations and the public service grant agencies that supply funding to the Broadway Center.
- b) Conduct daily multidisciplinary rounds - new admissions are reviewed and treatment planning takes place. Treatment approach utilizes primarily pharmacotherapy, cognitive-behavioral therapies, and treatment contingencies. Consult with clinic nursing and counseling staff, as well as other doctoral staff both in regular supervision and as needed to discuss current patient issues.
- c) Directly supervise senior and first-line clinical staff such as Senior Therapists, Addiction Therapists, Addiction Counselors, and Assessment Therapists. Also provided direct supervision to select administrative staff, including Program Manager.
- d) Conduct cognitive-behavioral group therapy sessions as needed, as well as weekly Treatment Re-evaluation team meetings, which are attended primarily by patients without optimal response to treatment.
- e) Conduct psychiatric evaluation as needed for patients exhibiting or reporting psychiatric symptoms.
- f) Provide 24 hours per day / 7 days per week pager coverage for administrative and clinical issues.
- g) Represent the Broadway Center in a range of Departmental and Hospital committees and meetings.
- 2009-present Medical Director, Johns Hopkins Hospital Broadway Center for Addictions (including OTP component). Responsible for clinical treatment within addiction treatment clinic approximately 200 outpatient slots. Treatment consisting of any of the following: Standard outpatient, intensive outpatient, methadone/buprenorphine opioid agonist maintenance, short-term detoxification services. In addition to duties described above as Director of this program, the Medical Director is responsible for direct supervision of all nursing and medical staff (RN, LPN, M.D., NP). The Medical Director is also ultimately responsible for the operation of the methadone dispensary, including assurance that all regulatory and narcotic accounting requirements are in compliance.
- 2009-present Staff Psychiatrist, Johns Hopkins Hospital. Attending Psychiatrist on inpatient acute psychiatric units approximately 2 months per year. Responsible for the management of psychiatric inpatients, lead multidisciplinary team rounds, and supervise psychiatric residents and medical students.
- 2018-present Interim Medical Director, Addiction Treatment Services at Hopkins Bayview (ATS). Dr. Stoller served as the first Medical Director on the ATS-MFL site. He has returned as ATS-BBRC and ATS-MFL Interim Medical Director of this nationally and internationally recognized substance use disorder treatment center, which serves as a site of NIH funded research and a training site for the Behavioral Pharmacology Research Unit fellowship, JHB/JHH psychiatry residency, and JH addiction medicine fellowship.

Clinical Productivity

More precise data available through the Johns Hopkins Hospital Department of Psychiatry and Behavioral Sciences. Dr. Stoller directs a highly productive outpatient program that is responsible for

43% of the outpatient visits of the entire department (at JHH), and is inpatient attending (2 months per year) on a unit that averages 50-60 inpatient discharges per month.

Clinical Program Building / Leadership

- 1998–2009 Medical Director, Addiction Treatment Services at Hopkins Bayview (ATS). The ATS-MFL is one of two clinical sites within the larger ATS entity, formed via administrative and clinical integration and restructuring of the Southeast Baltimore Drug Treatment Program and the Alcoholism Treatment Services program, along with approximately 1 million dollars in new services and funding. Dr. Stoller served as the first Medical Director on this site, and quickly instituted an NIH/NIDA-funded research protocol, establishing this site as one with stellar clinical as well as academic components. As part of the larger ATS entity, ATS-MFL has become a nationally and internationally recognized treatment center.
- 2000-2017 Assistant to the Medical Director of Behavioral Health, Johns Hopkins HealthCare, LLC. Since 2000, Dr. Stoller has served as the primary consultant to Johns Hopkins HealthCare (JHHC) on issues related to substance use disorders. With his guidance, JHHC restructured and refocused their care management division with the goal of using evidence-based practice to improve the health of their members, control costs, and become a leader in the field. These efforts focused on 1) integrating general medical and behavioral health care management practice, staff, information technology and training, 2) increasing detection treatment entry and treatment retention among members with substance use disorder, and 3) supporting efforts for national certification (e.g., NCQA), and 4) becoming a national leader in provision of innovative and evidence-based approaches to care management for managed care members with substance use disorders and co-occurring and complex medical, psychiatric and addictive disorders. By closely collaborating with the Director of Research (Dr. Peter Fagan), JHHC was awarded two research grants that examined clinical, administrative and economic outcomes of these initiatives. Research findings helped demonstrate, nationally, the feasibility and benefits of integrating mental health, addiction, and somatic health care within a Medicaid managed care organization.
- 2009-present Director, Medical Director, Johns Hopkins Broadway Center for Addictions. In July 2009 Dr. Stoller was assumed Directorship of this program, the outpatient addiction treatment center for Johns Hopkins Hospital. He is responsible for clinical and administrative direction, including direct supervision of staff, interacting with the Department on issues related to services, funding and budgets, interacting with other departments at Hopkins regarding patient flow and medical services provided, and interfacing with extra-Hopkins entities related to regulatory matters, funding/grants, and other opportunities. He has made great strides in his efforts, including 1) bringing in new sources of revenue and support; 2) increasing staff productivity, morale and use of evidence-based practice; 3) defragmenting clinic structures and instituting/leading a daily round for all clinicians; 4) forming/strengthening important links between the Broadway Center and other entities within the Department of Psychiatry, other departments and administrative entities within the Hospital, and agencies external to Hopkins (City, State and National levels); 5) correcting structures and practices that did not meet regulatory and/or accreditation body requirements; 6) restructuring staffing to address budgetary challenges and increase efficiency and oversight; and 7) working with Hospital leadership to address operational challenges related to new and proposed legislative changes. Since 2011, Dr. Stoller has also functioned as Medical Director, supervising all medical/clinical services and operations, and directly supervising all of the program's nurses, physicians, and nurse practitioners. Through his work at the Broadway Center, Dr. Stoller developed the nationally-recognized Collaborative Opioid Prescribing (“CoOP”) program, a hub-and-spoke model of care designed to increase buprenorphine access and quality by having opioid treatment programs function as hubs of expertise, collaborating with office-based buprenorphine prescribers.

Clinical Demonstration Activities to external audience, on or off campus

- April 2016 Hosted delegation (approximately 20) from Colombia, SA at the Broadway Center at the request of, and arranged through, the U.S. Department of State. Topic: Building an addiction treatment infrastructure.
- April 2015 Hosted health policy analysts (approximately 10) from Substance Abuse and Mental Health Association (SAMHSA) at the Broadway Center. Topic: Structured substance use disorder treatment in an opioid treatment program

Development of nationally/internationally recognized clinical standard of care (*may not be published in peer-reviewed journals*):

- 2013-present Developed a system of care to address the acute need for more, and higher quality, provision of buprenorphine treatment for opioid dependence. Dr. Stoller devised a system of care at the Broadway Center beginning in 2009, involving using the opioid treatment program component as a hub, and engaging with local office-based physician practices to have them get waivers to provide buprenorphine,

and prescribe for Broadway Center patients using an adaptive stepped care model extended to a hub and spoke system. Dr. Stoller promoted this model of care nationally through lectures, webinars, demonstration grants, and involvement in national professional associations. The Collaborative Opioid Prescribing (“CoOP”) model has been replicated in opioid treatment programs across the country, and used as a model by state addiction agencies as a strategy to expand availability of medication assisted therapies for opioid use disorder. The CoOP model is highlighted in a White Paper commissioned by SAMHSA which Dr. Stoller wrote on the use of opioid treatment programs as hubs of expertise, collaborating with other medical providers.

EDUCATIONAL ACTIVITIES

Teaching

Classroom instruction

| | |
|--------------|---|
| 1994-1996 | “Patient Interview Small Group” leader. Medical students. “Introduction to Psychiatry and Behavioral Sciences.” Johns Hopkins University School of Medicine |
| 1996 | Small group leader. Medical school students. “Human Sexuality.” Johns Hopkins University School of Medicine |
| 1999-2003 | Lecturer. Medical school and graduate school students. “Medical Pharmacology.” Various topics related to psychopharmacology. Johns Hopkins University School of Medicine (medical and graduate students). |
| 2000-2015 | Lecturer. Medical school students. “Introduction to Psychiatry.” Various topics, typically related to addiction. Johns Hopkins University School of Medicine. |
| 2005 | Lecturer. Graduate school students. “Prevention and Control of Mental Disorders.” Johns Hopkins Bloomberg School of Public Health. |
| 2006-2012 | Lecturer. Graduate school students. “Economics of Mental Health and Substance Abuse Disorders.” Johns Hopkins Bloomberg School of Public Health. |
| 2009 | Lecturer. Medical school students. “Genes to Society.” Johns Hopkins University School of Medicine. |
| 2010 | Lecturer. Medical school students. “Genes to Society” omnibus medical school course. “Brain, Mind, Behavior” component. Johns Hopkins University School of Medicine. |
| 2010-2013 | Lecturer. Medical school students. Psychiatry Clerkship. “Drug Addiction.” Johns Hopkins University School of Medicine. |
| 2010-present | Member of planning committee, course faculty. Medical school students. “Treatment of Substance Use Disorders” intersession/minimester course. Johns Hopkins University School of Medicine. |

Clinical instruction

| | |
|-----------|--|
| 1994-1999 | Clinical instruction. Psychiatric residents. Johns Hopkins Bayview Medical Center Emergency Department. Trained PGY-I psychiatric residents in logistics of on-call and how to perform emergency psychiatric evaluations and dispositions. Johns Hopkins University School of Medicine. |
| 1995-1996 | Clinical supervision. Psychiatric residents. Johns Hopkins Hospital Sexual Behaviors Consultation Unit. Supervised psychiatric resident evaluations, performed psychotherapy in continuing outpatient treatment. Johns Hopkins University School of Medicine. |
| 1997-2008 | Clinical instruction/lecturer. Train hospital addictions treatment staff regarding psychiatric assessment, diagnosis, and treatment, substance use disorders, and addiction treatment. Johns Hopkins Bayview Medical Center (Addiction Treatment Services and Community Psychiatry Programs). |
| 1998-2009 | Clinical instruction, supervision. Medicine/Psychiatric residents. Faculty in PGY-1 psychiatry rotation “Substance Use Disorders: Diagnosis, Comorbidity, and Treatment Approaches.” Location: Johns Hopkins Bayview Medical Center. Johns Hopkins University School of Medicine |
| 1999-2009 | Inpatient attending physician supervisor. Medicine/Psychiatry residents. Johns Hopkins Bayview Medical Center Acute Psychiatric Unit. Supervision and clinical instruction of PGY-1 residents and chief residents Johns Hopkins University School of Medicine |
| 1999-2009 | Inpatient attending physician supervisor. Medical students, Physician Assistant school students. Supervision and clinical instruction of medical school students and physician’s assistance school students during rotation. At Johns Hopkins Bayview Medical Center Acute Psychiatric Unit. Johns Hopkins University School of Medicine and various Physician Assistant programs. |
| 2000-2009 | Clinical instruction and supervision. Psychiatry residents. Johns Hopkins Hospital Psychiatry Residency Elective. Provide clinical supervision and education regarding substance abuse treatment to PGY-IV psychiatry residents during elective rotation At Johns Hopkins Bayview Addiction Treatment Services. Johns Hopkins University School of Medicine. |

- 2003-2007 Clinical instruction. Managed care organization staff. Care Management. Led Clinical Case Conference for Care Management and Behavioral Care Management staff. Discussed substance abusing members with co-occurring medical, psychiatric and pain disorders. Johns Hopkins HealthCare.
- 2008-2009 Clinical instruction. Medical school students. Psychiatric Clerkship, consultation-liaison rotation. Provide medical students an experience at Bayview's Addiction Treatment Services in substance abuse treatment, focusing on group psychotherapy (cognitive-behavioral) interventions. Approximately 2 students every 2-3 months. Johns Hopkins University School of Medicine.
- 2010-present Clinical instruction, supervision. Psychiatric residents. As attending physician, teach/supervise medical students and residents rotating through the clinical inpatient unit. Johns Hopkins Hospital Intensive Treatment Unit, Motivated Behaviors Unit, Johns Hopkins University School of Medicine.
- 2014-present Didactic instructor re: treatment of substance use disorders. Medical residents. Urban Health Residency Substance Use Disorders Rotation. Johns Hopkins Hospital, Johns Hopkins University School of Medicine.

CME/CE instruction (vast majority were invited)

JHMI/Regional:

- 2005 Faculty. Various clinicians. *"An adaptive treatment approach to adjust intensity and motivate patient attendance."* Johns Hopkins Bayview Medical Center. Continuing education approved seminar on substance use and psychiatric disorders. Baltimore, MD
- 2007-2009 Faculty. Various clinicians. *"Clinical Access to Specialized Treatment (CAST)"*. Sponsored by Baltimore Substance Abuse Services. Continuing education seminar series (occurring quarterly) to train addiction treatment clinicians from the Baltimore Metropolitan area on specialized treatment for substance abuse patients, including psychiatric co-occurring disorders and chronic pain disorders. Titles (selected) such as Treatment of Patients with Substance Use and Other Psychiatric Co-occurring Disorders, Measured Paternalism and Motivated Stepped Care, and Adaptive Paternalism and Motivated Stepped Care. Johns Hopkins Bayview Medical Center, Baltimore, MD
- 2009-2013 Faculty. Physicians. *"Buprenorphine Certification Training"*. Johns Hopkins Medicine Continuing Medical Education. Lectures included: a) Overview of Methadone, Naltrexone and Clonidine in the Treatment of Opioid Dependence; b) Buprenorphine Maintenance: Patient Assessment and Selection; c) Psychiatric Co-Occurring Disorders. Baltimore, MD
- 2016 Faculty. Clinical and governmental agency leaders (Maryland). *"CoOP: Integrative buprenorphine treatment – increasing access and quality of care to address Maryland's overdose epidemic."* Maryland Behavioral Health Administration, Department of Health and Mental Hygiene. Integrative Overdose Prevention Strategies & Practices Conference. 11/17/16, Ellicott City, MD
- 2016 Faculty. Clinical and governmental agency leaders (Philadelphia metro area). *"Innovative Practices in Buprenorphine Treatment and Primary Care Coordination"* Panel Discussion, and closed meeting with City officials. Buprenorphine Summit: Population Health Approaches to the Opioid Epidemic. Sponsored by Philadelphia Department of Behavioral Health and Intellectual disABILITY Services 9/2/16 Philadelphia, PA
- 2016 Faculty. Various clinicians. *"The CoOP Model: Improving Office-Based Buprenorphine Access and Quality through Collaboration."* Lecture during Johns Hopkins Medicine Road to Recovery Conference 9/26/16 Baltimore, MD

National:

- 2001 Lecturer and small group discussion facilitator. Physicians. *"Buprenorphine in Office-based Treatment of Opioid Dependence"*. Sponsored by American Society of Addiction Medicine and American Academy of Addiction Psychiatry. 8-hour course required to gain permission to deliver buprenorphine maintenance services. Philadelphia, PA
- 2004 Workshop Leader. Physicians. *"Topics in Psychiatry, Fourth Annual Course."* National program sponsored by the Johns Hopkins University School of Medicine. Led workshop on *"Methadone and Buprenorphine: Long-Term Agonist Treatment of Opiate Addiction."* Baltimore, MD
- 2011 Faculty. Various clinicians. Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Division of Pharmacologic Therapies. *"Education, Training and Professional Development of Health Care Providers in Opioid Treatment Programs"* (aka "MedEdTa"), Nationwide series of continuing educational and professional development seminars. Lectures I have given include: 1) *"Initial Screening, Admissions Procedures and Assessment Techniques"* 2) *"Drug Testing as a Tool"* 3) *"Patient Treatment."* Burlingame, CA

- 2013 Workshop organizer/leader. Various clinicians. “*Sedatives in Opioid Treatment Programs: Clinic Policies and Procedures.*” Workshop: “Benzodiazepine risk and management in OTPs” at the 2013 National Conference of the American Association for the Treatment of Opioid Dependence. Philadelphia, PA
- 2014 Invited seminar speaker. Various disciplines. “*Non-pharmacologic Treatments for Alcohol Use Disorder.*” Seminar: “Evidence-Based Approaches to Alcohol Detoxification and Treatment.” American Society for Addiction Medicine’s 45th Annual Medical-Scientific Conference. Orlando, FL
- 2014 Moderator, Symposium Presenter. Researchers, clinicians. “*The Opioid Treatment Program: A Uniquely-Suited Setting for Provision of Integrative Care.*” 2014 Addiction Health Services Research (AHSR) Conference. Boston, MA.
- 2015 Faculty. Physicians. Substance Abuse and Mental Health Administration; and American Academy of Addiction Psychiatry and SAMHSA. “*Buprenorphine for the Treatment of Opioid Dependence in Office-Based Treatment and Opioid Treatment Programs.*” Buprenorphine waiver training provided at the American Association for the Treatment of Opioid Dependence conference. Atlanta, GA.
- 2016 Workshop speaker. Clinicians, policymakers. “*Transforming Addiction Treatment through Innovative Models of Care: Insights from Maryland.*” American Society of Addiction Medicine Annual Conference. Baltimore, MD
- 2016 Plenary Chair. American Association for the Treatment of Opioid Dependence National. Organized and secured speakers for three plenary sessions. Speakers included the U.S. Surgeon General, the Director of the White House Office of National Drug Control Policy, Director of SAMHSA’s Center for Substance Abuse Treatment, the Maryland Lieutenant Governor, the Deputy Director of the United Nations Office of Drugs and Crime, the Administrator of the U.S. Drug Enforcement Administration, and others. Baltimore, MD
- 2016 Faculty. Physicians. “*Buprenorphine for the Treatment of Opioid Dependence in Office-Based Treatment and Opioid Treatment Programs.*” Course sponsored by Substance Abuse and Mental Health Administration and American Academy of Addiction Psychiatry and SAMHSA. Buprenorphine waiver training provided at the American Association for the Treatment of Opioid Dependence conference. Baltimore, MD.
- 2016 Faculty. Various clinicians. “*Clinician’s Course.*” Role: Faculty, planning committee. 8-hour course given at American Association for the Treatment of Opioid Dependence National Conference. Baltimore, MD.
- 2016 Faculty. Various clinicians and governmental agency leaders. “*CoOP: Improving MAT Access and Quality Through Collaboration: A Role for Primary Care.*” Lecture and panel discussion at Substance Abuse and Mental Health Services Administration’s National Block Grant Conference: Building and Sustaining State Behavioral Healthcare Systems. 8/9-11/2016 Arlington, VA
- 2016 Webinar co-presenter. Physicians primarily. “*Methadone: Its Role in Opioid Addiction Treatment vs. Pain Management.*” Webinar sponsored by the American Society of Addiction Medicine and SAMHSA’s Provider Clinical Support System (PCSS-MAT), 8/2016. <http://pcssmat.org/wp-content/uploads/2016/08/PCSS-MAT-Module-Olsen-and-Stoller-FINALPPT.pdf>
- 2016 Webinar co-presenter. Physicians primarily. “*PCSS Follow-up Webinar: Methadone: Its Role in Opioid Addiction Treatment vs. Pain Management.*” Webinar sponsored by the American Society of Addiction Medicine and SAMHSA’s Provider Clinical Support System (PCSS-MAT), 9/2016.
- 2018 Faculty. Various clinicians. “*Clinician’s Course.*” Role: Faculty, planning committee. 8-hour course given at the 2018 National Conference of the American Association for the Treatment of Opioid Dependence. New York, NY.
- 2018 Co-Speaker. Various clinicians. “*A Programmatic Approach to Benzodiazepine Use Among OTP Patients.*” Workshop: “Concurrent Use and Misuse of Benzodiazepines Among Patients Receiving Pharmacotherapy for Opioid Use Disorder” at the 2018 National Conference of the American Association for the Treatment of Opioid Dependence. New York, NY.
- 2018 Co-Speaker. Various clinicians. “*Methadone 101.*” 2018 National Conference of the American Association for the Treatment of Opioid Dependence. New York, NY.
- 2018 Speaker. Physicians primarily, other clinicians. “*Medications for Addiction Treatment: What Medical Providers, Specialists Should Know.*” Johns Hopkins Medicine 14th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases. Baltimore, Maryland.

Workshops /seminars

JHMI/Regional:

2005-2012 Organizer, lecturer. Therapists. “*Psychopathology.*” Recurring series covering diagnosis and treatment of a range of psychiatric disorders. ATS at Johns Hopkins Bayview Medical Center (2005-2009), and Johns Hopkins Broadway Center (2011-2012), Baltimore, MD

National: (Above, see CME/CE-granting activities section)

Mentoring

Pre-doctoral Advisees /Mentees

- 2009 Michelle R. Hawkins, MSN, MBA, RN, CCM. Capstone Project mentor. Johns Hopkins University School of Nursing. Advisor to doctoral candidate's Comprehensive Project Plan (NUR 210.897). Resource for the coordination of care between behavioral health and care management within Johns Hopkins HealthCare, LLC. Educate care management staff and select clinical leadership on the effects of substance abuse on chronic illnesses and participate in case discussions.
- 2012-2014 Paige Nichols, Anne Lin. Johns Hopkins University. Preceptor for Baccalaureate and Post-Baccalaureate Tutorial – “Substance Abuse Treatment: Program Administration and Quality Improvement.”
- 2014-2015 Christopher Louie. MPH Practicum preceptor. Johns Hopkins University Bloomberg School of Public Health.

Post-doctoral Advisees /Mentees

- 1998-2010 James Carter, Ph.D.; James Ettier, M.D.; Christopher Burke, Ph.D., Will Aklin, Ph.D., David Andrew Tompkins, M.D., Shauna P. Acquavita, PhD, LCSW-C, BCD. Post-doctoral research and clinical mentor. Johns Hopkins University School of Medicine. Mentorship to psychiatric residents and post-doctoral fellows (Ph.D. and M.D.) through BPRU/ATS. Provide regular clinical supervision, as well as guidance as it relates to research in addiction psychiatry.
- 1999 Medhat Bassiony, M.D.; Amany El Mougy, M.D. Johns Hopkins University School of Public Health. Coordinated education experience and provided mentorship for international Humphrey Fellows rotating through Addiction Treatment Services at Hopkins Bayview.
- 2000-2009 James Carter, Ph.D., Jessica Peirce, Ph.D. Johns Hopkins University School of Medicine. Clinical mentorship to junior faculty (Ph.D., M.D.) at ATS. Provide regular clinical supervision, as well as guidance as it relates to research in addictions psychiatry.
- 2009-present Anika Alvanzo, M.D., Elizabeth Disney, Ph.D., Anne Ruble, M.D., Vinay Parekh, M.D. Johns Hopkins University School of Medicine. Provide clinical and research mentorship to junior faculty at the Johns Hopkins Broadway Center for Addiction. Provide regular clinical supervision, guidance as it relates to research in addictions psychiatry, and mentorship/guidance related to leadership development.
- 2015-present Brendan Saloner, Ph.D. Clinical mentor including on NIH K award (*DA042139-01A1 Improving Access and Quality of care for Medicaid-Eligible Adults with Opioid Use Disorder. 04/01/2017 – 03/31/2022. \$183,545 per year*). Johns Hopkins University School of Medicine and Bloomberg School of Public Health. Mentorship focus: clinical issues in psychiatry and addiction for junior faculty for academic/research endeavors.

Thesis committees

- 2009-2011 Johns Hopkins Bloomberg School of Public Health. Dissertation Advisor for Ph.D. candidate Alyson Schuster, Department of Health Policy and Management. Successful Completion. Title: “Comparison of Buprenorphine and Methadone Use in a Medicaid Managed Care Organization.” Goal is to describe the characteristics and health services use of Medicaid MCO enrollees who receive buprenorphine treatment, and to compare these members to those who receive methadone maintenance.

Training grant participation

- 1998-present “Human Behavioral Pharmacology of Substance Abuse”. Johns Hopkins University School of Medicine, Department of Psychiatry. NIDA 5T32 DA07209. PI: George Bigelow, Ph.D. Provide mentorship to postdoctoral fellows in their experience at Addiction Treatment Services at Hopkins Bayview. Provide regular clinical supervision, as well as guidance as it relates to research in addiction psychiatry.

RESEARCH ACTIVITIES

Research Focus

Dr. Stoller is a well-regarded national expert on opioid addiction. He has developed, evaluated and disseminated models of care geared toward multi-morbid populations that are integrative and promote adherence. His most impactful focus has been on collaborative care models, treatment access, program building, health policy, and healthcare utilization/cost. He developed and disseminated a collaborative opioid prescribing (“CoOP”) model which has received high level attention from SAMHSA, ONDCP, and professional societies, and has been instituted by programs and localities nationwide. Dr. Stoller is deeply-engaged with local, state and national associations and governmental agencies engaged in addressing the opioid epidemic.

Research Program Building / Leadership

- 1998-2009. Researcher. Opioid addiction treatment. Implemented research infrastructure and first research project in newly developed opioid addiction treatment clinic on the Bayview Campus (Addiction Treatment Services at Hopkins Bayview, Mason F. Lord Building). Study was funded by NIH-NIDA (P50 DA-05273, PI: G. Bigelow). The research infrastructure established at that time still remains in place, and has been utilized in a number of subsequent sponsored and unsponsored research projects, including NIH-funded studies.
- 2002-2017. Researcher. Addiction in managed care. Work closely with Johns Hopkins HealthCare staff (most notably with Peter Fagan, Ph.D. – former Director of Research) to establish a strong line of research and quality improvement initiatives in the area of relationships between substance use problems, substance use problem treatment, medical disorders, medical service utilization and cost, mental illness, and chronic pain. These efforts have led to 2 extramurally-funded research grants and numerous scholarly presentations, in addition to improved quality of care of JHHC members. Dr. Stoller was formally offered salary support (\$30,000) to continue these and more clinical efforts as of July 2008 to 2017.
- 2014-present. Faculty. Center for Mental Health and Addiction Policy Research (CMHAPR). Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine. Aim: to improve the lives of persons with mental illness and addiction through engaging in policy research, translating research evidence into policy and practice, and training a next generation of mental health and addiction policy researchers. www.jhsph.edu/cmhapr

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES

System Innovation Focus

Dr. Stoller is recognized nationally for his expertise in developing and implementing systems that improve both access, as well as quality, of treatment services for substance use problems. For example, shortly after assuming Directorship of the JH Broadway Center, he instituted a collaborative buprenorphine model (a hub-and-spoke model of care) that has enabled more patients to access buprenorphine treatment in nearby office-based medical practices, while assuring ongoing counseling in his program, with exemplary outcomes. His focus on ways to enhance engagement, motivate attendance, and structure treatment have led to consistent high-quality care and national recognition.

System Innovation and Quality Improvement efforts within JHMI:

- 2000 Johns Hopkins Bayview Medical Center Joint Practice Committee Aftercare Project Subcommittee
- 2003 Johns Hopkins Bayview Medical Center, Acute Psychiatric Unit – Addiction Treatment Services Clinical/Training Coordination project.
- 2007 Johns Hopkins Medicine. Member of workgroup with the purpose to improve training of physicians at Johns Hopkins in the use of buprenorphine maintenance pharmacotherapy (led by E. Strain, M.D.)
- 2008 Johns Hopkins Bayview Medical Center Care Center: Invited member of Care Center Resident Substance Use Problems workgroup
- 2008-2015 Johns Hopkins HealthCare, LLP. Member, Buprenorphine Committee. Mission: to create a system of authorization and management of buprenorphine treatment among JHHC members consistent with excellent clinical practice.
- 2009 Johns Hopkins Bayview Medical Center Pain Management Operations Subcommittee. Goal: to develop the procedures for referral, consultation, and integration of a pain management service.
- 2009-2013 Johns Hopkins HealthCare Committee on Opioid Use and Addiction. Mission: to better recognize and manage members with problematic opiate use, improve treatment system, and limit unnecessary cost.
- 2009-present Johns Hopkins HealthCare, LLP. Member, Medical Policy Committee (renamed Quality Assurance and Performance Improvement committee). This is one of the primary committees with a focus on quality improvement and quality assurance within all lines of business at Johns Hopkins HealthCare.
- 2009-2010 Johns Hopkins Hospital Department of Psychiatry. Member, Committee of Substance Abuse Service Reorganization. Committee was charged with, and produced a report to the Center for Substance Abuse Treatment and Research regarding recommendations for reorganization of substance abuse inpatient and outpatient services at JHH.
- 2009-present Johns Hopkins Hospital Department of Psychiatry. Member, Performance Improvement Committee. Ongoing committee charged with reviewing ongoing performance improvement initiatives and communicating issues that may require practice revision within the Department units.
- 2009-present Johns Hopkins Medicine. Member, Substance Abuse Steering Committee, Attended by addiction treatment and general leadership within JHM. Major quality improvement initiatives are discussed and presented in this forum. Served on subcommittee for information technology and data analysis.

- 2009-2012 Johns Hopkins Medicine. Member, SA Metrics and Outcomes Workgroup. Goal: create a common data collection system to track specific process, outcome measures among inpatient and outpatient addiction treatment units throughout JHM.
- 2010-2011 Johns Hopkins Hospital Department of Psychiatry. Member, Alcohol Withdrawal Assessment Project Committee. Goal: Create protocols and train staff to systematically assess for and treat alcohol withdrawal among JHM inpatients.
- 2010 Johns Hopkins HealthCare, LLP. Member of Substance Abuse Workgroup charged with developing strategies to improve identification of substance-addicted members and engagement in treatment.
- 2010 Johns Hopkins Hospital. Participant, Safety Attitudes Questionnaire (SAQ) Focus Group for Improved Safety and Teamwork. Invited due to the “outstanding improvement” in SAQ scores of Dr. Stoller’s reportees at the Johns Hopkins Broadway Center
- 2015-present Johns Hopkins Bloomberg School of Public Health. Mental Health and Addiction Policy Research Collaborative. Core faculty member.
- 2015-2016 Johns Hopkins Hospital Department of Psychiatry. Member, Executive Quality Improvement Committee. Ongoing committee charged with reviewing ongoing quality indicators and ongoing QI processes within the Department. Disbanded in 2016.
- 2015-2016 Johns Hopkins Medicine. Member, Prescription Drug Monitoring Program Workgroup charged with developing recommendations regarding recommended and/or mandated use of the PDMP by medical providers and pharmacies at JHM entities.
- 2015-2017 Johns Hopkins East Baltimore Medical Center. Member, Buprenorphine Expansion Workgroup, charged with expanding and enhancing use of buprenorphine for treatment of opioid use disorder.

System Innovation and Quality Improvement efforts outside of JHMI:

- 2006-2010 Member, Center for a Healthy Maryland / Med Chi Buprenorphine Advisory Committee. Statewide but small committee comprised of experts in the field of substance abuse treatment within the state of Maryland, and charged with increasing capacity for effective medically assisted treatment for opioid dependence and office-based treatment. These efforts resulted in white papers, state-wide recommendations to and the State legislature, as well as a number of statewide trainings regarding the safe, effective and efficient delivery of office-based opioid treatment using buprenorphine.
- 2010-2011 National Faculty Expert. Substance Abuse and Mental Health Service Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Division of Pharmacologic Therapies. MedEdTA: Opioid Treatment Program (OTP) Clinical Staff Education: Appropriate Use of Methadone in the OTP. Selected as nationally recognized expert in the treatment of opioid dependence, as regular faculty lecturer/leader in a series of nationwide training curriculum. The goal of this project is to improve overall quality and safety of care delivered in comprehensive opioid treatment programs nationwide, particularly in consideration of recent upward trends in reports of fatal methadone overdoses.
- 2010-2012 Member, State of Maryland Department of Health and Mental Hygiene’s Substance Abuse Access and Outcomes Data Group. This is a statewide committee of clinical, governmental, managed care, and governmental leaders tasked with using ongoing data measurement to drive quality improvement and system revision within the State of Maryland’s substance abuse treatment system.
- 2013-2016 Member, State of Maryland Department of Health and Mental Hygiene’s OTP Quality Improvement Committee. Tasked with improving overall quality of care in opioid treatment programs in Maryland.
- 2014-2015 Member, Baltimore Mayor’s Office and Behavioral Health Systems Baltimore, Inc. Invited to serve on Heroin & Other Substance Use Treatment Improvement Task Force. Practice Standards Workgroup.
- 2015-2016 Member, State of Maryland Department of Health and Mental Hygiene. Behavioral Health Administration’s Workgroup on Specialized Credentialing in Medication Assisted Therapy. Group is tasked with improving training of professional therapists and counselors on issues related to medication assisted therapies for substance use disorders.
- 2015-present Member, State of Maryland Department of Health and Mental Hygiene. Buprenorphine Expansion Workgroup. Tasked with increasing certified prescribers and support to prescribers, and facilitating access to recovery support resources for patients on buprenorphine in the State of Maryland.
- 2016 Member, Substance Abuse and Mental Health Service Administration (SAMHSA). Opioid Treatment Program (OTP) Advisory Panel. Tasked with identifying appropriate performance and outcome measures that could be incorporated into a national OTP performance monitoring system.
- 2016-2017 Member, Behavioral Health Systems Baltimore and Baltimore City Health Department’s Buprenorphine Expansion Workgroup.
- 2016 Paid Consultant, SAMHSA Region 8 Medication Assisted Therapy (MAT) Meeting in Denver, CO 8/31/2016-9/1/2016. Purpose of this clinical and state agency leadership conference was to improve

- access and quality of MAT in Colorado, Montana, North Dakota, South Dakota, Utah, and Wyoming. Dr. Stoller provided formal lectures, ran small groups sessions, participated in panel discussions.
- 2017 Advisor. Met in D.C. Senate to provide guidance to Committee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security Ranking Member Bernie Sanders (I-VT). January 2017
- 2017-present Member, Maryland Hospital Association's Behavioral Health Taskforce. Participation in Opioid Epidemic Work Group.
- 2017-present Member, Bloomberg American Health Initiative – Addiction and Overdose Workgroup. Johns Hopkins Bloomberg School of Public Health.
- 2017-present Working with leadership at American Academy of Addiction Psychiatry (Kathryn Cates-Wessel) and American Association for the Treatment of Opioid Dependence (Mark Parrino) to create a guidebook reference for the use of telemedicine in opioid treatment programs.
- 2017-present Initiated a workgroup, now led by Regional SAMHSA Administrator Jean Bennett, "Social Workers-Substance Use Workforce Development." Purpose of workgroup is to build a qualified addiction workforce through enhancing education in the addictions within schools of social work, and support ongoing professional training among social workers.
- 2017 Member of group assisting Delaware in improving its statewide system for medically assisted treatment for opioid use disorder. Contact - Director, Delaware Division of Public Health. (Received some salary support for efforts)
- 2017-present Designated as one of 3 "Expert Consultants" by SAMHSA Leadership (Jean Bennett, Region 3 Administrator) for initiative: "MAT Expansion Project", constituted by series of meetings and conference calls with participants from 6 states. Each state is instituting a project to expand medication treatments for opioid use disorder.
- 2018-present Invited Participant, Maryland's Opioid Operational Command Center. Established by Maryland Governor Executive Order. Provides an over-arching picture of Maryland's Heroin and Opioid crisis to understand the current landscape and build upon ongoing community-based approaches to address this crisis by increasing collaboration between state and local public health, human services, education, and public safety entities.
- 2018-present Invited Member, The Joint Commission Behavioral Health Care Advisory Council. Comprised of individuals, with expertise in the field of Behavioral Health Care. Objective is to assist in driving TJC mission of evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value through our behavioral health care accreditation program.
- 2017-2021 Invited federal appointment by the Secretary of the U.S. Department of Health and Human Services. SAMHSA Center for Substance Abuse Treatment National Advisory Council. Members advise, consult with, and make recommendations to the Secretary, the SAMHSA Administrator and the CSAT Director concerning matters relating to the activities carried out by and through the Center, and the policies respecting such activities.

System Innovation and Quality Improvement Program Building/Leadership:

- 1998-2009 Johns Hopkins Bayview, Addiction Treatment Services, Mason F. Lord Building site. Clinic establishment and implementation of Adaptive Stepped Care model of treatment. Dr. Stoller served as the first Medical Director on this site, and quickly implemented an NIH/NIDA-funded research protocol (PI: R. Brooner), establishing this site as one with stellar clinical as well as academic components. As part of the larger ATS entity, ATS-MFL has become a nationally and internationally recognized treatment center. Winner of The Joint Commission's coveted Ernest Amory Codman Award in 2007. The Codman Award is the first health care award that recognizes excellence in performance measurement.
- 2009-present Johns Hopkins Broadway Center for Addiction. Directed reorganization of programs formally known as the Program for Alcohol and Other Drug Dependence and the Comprehensive Women's Center. Designed and implemented a major reorganization of the clinical structure of the program. Demonstrated positive results including: 1) bringing in new sources of revenue and support; 2) increasing staff productivity, morale and use of evidence-based practice (Safety Attitudes Questionnaire score increase was among the top 10 of all JHH units); 3) defragmenting clinic structures and instituting/leading a daily round for all clinicians; 4) forming/strengthening important links between the Broadway Center and other entities within the Department of Psychiatry, other departments and administrative entities within the Hospital, and agencies external to Hopkins (City, State and National levels); 5) correcting structures and practices that did not meet regulatory and/or accreditation body requirements; 6) restructuring staffing to address budgetary challenges and increase efficiency and

oversight; and 7) working with Hospital leadership to address operational challenges related to new and proposed legislative changes. Continuing efforts on system innovation and quality improvement focus on: 1) establishment of the Broadway Center as a site of clinical education; 2) Establishing research activities in the Center; 3) restructuring the Center's Health Suite; and 4) establishing an electronic patient record and comprehensive data tracking system.

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

- 1996-2009 Member, Executive Direction Committee. Addiction Treatment Services at Johns Hopkins Bayview Medical Center.
- 1997 Member, Senior Staff Committee and Postdoctoral Representative. Behavioral Pharmacology Research Unit Senior Staff Committee. Johns Hopkins University School of Medicine.
- 1998-2009 Member, Johns Hopkins Bayview Medical Center Substance Abuse Community Advisory Board
- 2000 Member, Johns Hopkins Bayview Medical Center Joint Practice Committee for Psychiatry. Member of Aftercare Project Subcommittee
- 2003 Project Member. Johns Hopkins Bayview Medical Center, Acute Psychiatric Unit – Addiction Treatment Services Clinical/Training Coordination project.
- 2004 Member, Collaborative Services Delivery Research focus group. Johns Hopkins University Department of Psychiatry and Bloomberg School of Public Health
- 2007 Member, Johns Hopkins Medicine workgroup tasked with improving the training of physicians at Johns Hopkins in the use of buprenorphine maintenance pharmacotherapy
- 2008 Member, JHBMC Care Center Substance Use Problems Workgroup. Johns Hopkins Bayview Medical Center Care Center.
- 2008-2017 Assistant to the Medical Director for Behavioral Health, Johns Hopkins HealthCare, LLP. Perform reviews of member cases for members of insurance lines who require psychiatric or substance abuse services when physician review is required in the absence of the Medical Director. Also function in administrative role pertaining to systematic changes in care management programs, and organize/lead educational activities for behavioral health section.
- 2008-2012 Member, Johns Hopkins HealthCare Buprenorphine Committee. (Mission: to create a system of authorization and management of buprenorphine treatment among JHHC members consistent with excellent clinical practice, and to establish a basis of research in this topic area.)
- 2009 Member, Johns Hopkins Bayview Medical Center Pain Management Operations Subcommittee. (Goals: to develop the procedures for referral, consultation, and integration of a pain management service.)
- 2009-2013 Member, Johns Hopkins HealthCare Committee on Opioid Use and Addiction. (Mission: to better recognize and manage members with problematic opiate use, improve treatment system, and limit unnecessary cost.)
- 2009-present Member and Behavioral Health Representative, Medical Policy Committee (Renamed Quality Assurance and Performance Improvement Committee). Johns Hopkins HealthCare, LLP.
- 2009-2013 Member, Committee on Medical School Admission. Johns Hopkins University School of Medicine.
- 2009-2011 Member, Committee of Substance Abuse Service Reorganization, Johns Hopkins Hospital Department of Psychiatry.
- 2009-present Member, Quality Improvement Committee. Johns Hopkins Hospital Department of Psychiatry.
- 2009-present Member, Substance Abuse Steering Committee, Johns Hopkins Medicine.
- 2009-present Member, Substance Abuse Service Line Committee. Johns Hopkins Hospital.
- 2009-present Member, Regulatory Compliance Committee. Johns Hopkins Hospital.
- 2009-present Member, Compliance Committee. Johns Hopkins Hospital Department of Psychiatry.
- 2010-2011 Member, Alcohol Withdrawal Assessment Project Committee. Johns Hopkins Hospital Department of Psychiatry.
- 2010 Member, Substance Abuse Workgroup. Charged with developing strategies to improve identification of substance-addicted members and engagement in treatment. Johns Hopkins HealthCare, LLP.
- 2010 Participant, Johns Hopkins Hospital Safety Attitudes Questionnaire (SAQ) Focus Group for Improved Safety and Teamwork. Invited as a result of outstanding improvement in SAQ scores at the Johns Hopkins Broadway Center.
- 2011-2015 Advisory Council member, Johns Hopkins Center for Health Policy and Healthcare Transformation.
- 2013 Member, Johns Hopkins Hospital Department of Psychiatry. Substance Abuse Inpatient Service Reorganization Committee.

2014 Member, Johns Hopkins Hospital Department of Emergency Medicine Pain Management Task Force.

Journal peer review activities

1997 - Drug and Alcohol Dependence
1998 - Psychopharmacology
2001 - Addiction
2002 - Pharmacoeconomics
2009 - Expert Review of Pharmacoeconomics & Outcomes Research
2010 - Journal of Addiction Medicine
2013 - Journal of Dual Diagnosis

Advisory Committees, Review Groups/Study Sections

2001-2002 Panel Member, Linking Treatment of Substance Abuse and HIV/AIDS. Advisory panel composed of representatives from addiction and HIV treatment programs in Baltimore

2002-2014 Consultant and Educator, Priority Partners MCO Substance Abuse Sub-Committee addressing issues regarding behavioral health and the interplay between psychiatric illness, substance use problems, chronic pain, and somatic medical disorders.

2002-2008 Workgroup Member, Maryland HealthChoice Substance Abuse Workgroup charged with standardizing and optimizing the statewide system of care for Medicaid recipients with substance abuse.

2004 Invited Member, Substance Abuse and Mental Health Administration, U.S. Department of Health and Human Services. Special Emphasis Grant Review Panel II on Knowledge Application Program.

2005-2008 Data Safety and Monitoring Board member, Friends Research Institute, Inc. "Methadone Maintenance for Prisoners," NIH-NIDA Grant No. 1 R01 DA016237. Friends Research Institute (PI: T. Kinlock).

2006-2010 Committee Member, Center for a Healthy Maryland / Med Chi Buprenorphine Advisory committee. Statewide committee comprised of experts in the field of addiction treatment, charged with increasing capacity for effective medically assisted treatment for opioid dependence and office-based treatment.

2008-2012 Data Safety and Monitoring Board member, Friends Research Institute, Inc., "Suboxone for Prisoners," NIH-NIDA Grant 1 R01 DA021579-01. Friends Research Institute (PI: T. Kinlock).

2008-2011 Data Safety and Monitoring Board member, Friends Research Institute, Inc. "Entry into Comprehensive Methadone Treatment via Interim Maintenance," NIH-NIDA Grant. Friends Research Institute (PI: R. Schwartz).

2009-present Executive Committee, Maryland Association for the Treatment of Opioid Dependence (MATOD). Provider Committee member (2009-2012); Executive Committee member (2012-present).

2009 Curriculum reviewer, National Institute on Drug Abuse Centers of Excellence for Physician Information. Participated as a reviewer of curriculum resources developed to improve education on addiction and other behavioral disorders.

2009-2013 Member, National Council on Alcoholism and Drug Dependence of Maryland (NCADD-Maryland), Served on the Addiction Treatment Advocates Committee.

2009-present Member, Baltimore City Substance Abuse Directorate.

2009-2013 Member, Maryland Addiction Directors Council (MADC).

2009 Grant Reviewer, National Institutes of Health, National Institute on Drug Abuse. Behavioral Science Track Award for Rapid Transition (B/START) program, October 2009.

2010-2013 Data Safety and Monitoring Board member, Friends Research Institute, Inc. "Intensive Outpatient v. Outpatient Treatment with Buprenorphine among African Americans," NIH-NIDA Grant DA028407-01. Friends Research Institute (PI: S. Mitchell).

2010-2012 Data Safety and Monitoring Board member, Friends Research Institute, Inc. "SBIRT in New Mexico," NIH-NIDA Grant 1 R01 DA-26003-01. Friends Research Institute (PI: R. Schwartz).

2010-2012 Member, State of Maryland Department of Health and Mental Hygiene. Substance Abuse Access and Outcomes Data Workgroup.

2010 Physician Educator, Maryland law enforcement and judicial system. MATOD-initiated committee charged with educating law enforcement and judges about opioid maintenance therapy.

2011-2017 Data Safety and Monitoring Board member, Friends Research Institute, Inc. "Reengineering Methadone Treatment: A Clinical Trial," NIH-NIDA Grant 2 R01 DA-015842-06. Friends Research Institute (PI: R. Schwartz).

2012-2016 Member, State of Maryland's Behavioral Health Administration Opioid Treatment Program Improvement Committee

2012-present Member, Board of Directors, Medications Committee member, Representative from State of Maryland to the American Association for the Treatment of Opioid Dependence (AATOD). Also representative to

- the SAMHSA Provider Clinical Support System steering committee, Plenary Chair and Associate Chair of 2016 AATOD National Conference.
- 2012-present Steering Committee member, Providers Clinical Support System for Medication Assisted Treatment (PCSS-MAT); SAMHSA-funded grant. AATOD representative.
- 2012-present Steering Committee member, Providers' Clinical Support System for Opioid Therapies (PCSS-O); SAMHSA-funded grant. AATOD representative.
- 2013-present MedChi, the Maryland State Medical Society. Member, Addictions Committee.
- 2014 Data Safety and Monitoring Board member, Friends Research Institute, Inc. "Health Service Research: Extended Release Naltrexone for Opioid-Dependent Youth," NIH-NIDA Grant 1R01DA033391. Friends Research Institute (PI: S. Mitchell).
- 2015-2017 Data Safety and Monitoring Board member, Friends Research Institute, Inc. "A Randomized Trial of SBIRT Services in School-Based Health Centers," NIH-NIDA Grant 1 R01 DA-036604-01. Friends Research Institute (PI: J. Gryczynski).
- 2017 Invited member of Expert Panel (as Subject Matter Expert). U.S. Substance Abuse and Mental Health Administration. "Concurrent Use and Misuse of Benzodiazepines and/or Alcohol among Patients Receiving Pharmacotherapy for Opioid Use Disorder (OUD)." Convened in the service of creating a new published set of guidelines.
- 2017 Field Reviewer. U.S. Substance Abuse and Mental Health Administration. TIP (Toolkits for Improving Practice) titled "Medications for Opioid Use Disorder"

Professional Societies

- 1988-2002 American Medical Association. Member.
- 1992-present American Psychiatric Association. Fellow. Designated as a "Research Expert." APA Council on Addiction Psychiatry. 5/2017 – 5/2018.
- 1992-present Maryland Psychiatric Society. Member. Residents and Fellows Committee (1993-1998).
- 2008-2010 National Alliance on Mental Illness. Professional Member.
- 2008-present American Psychopathological Association. Member.
- 2011-present College on Problems of Drug Dependence. Member.
- 2018-present American Academy of Addiction Psychiatry. Member.

Conference Organizer

National:

- 10-11/2016 Plenary Chair, Associate Conference Chair. American Association for the Treatment of Opioid Dependence (AATOD). AATOD National Conference (with international components). Baltimore, Maryland.

Session Chair

National:

2005. Session Chair of the Scientific and Clinical Report Session entitled, "Addiction Psychiatry" at the 2005 American Psychiatric Association Annual Meeting, Atlanta, Georgia.
- 2014 Session Chair, symposium moderator, presenter: "The Opioid Treatment Program: A Uniquely-Suited Setting for Provision of Integrative Care." Activity: 2014 Addiction Health Services Research (AHSR) Conference. Boston, Massachusetts

Consultantships

- 2000 Consultant Reviewer for Center for Substance Abuse Treatment (CSAT), Substance Abuse Mental Health Services Administration (SAMHSA). Buprenorphine Clinical Practice Guidelines.
- 2000 Consultant Reviewer for Center for Substance Abuse Treatment (CSAT), Substance Abuse Mental Health Services Administration (SAMHSA). Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence: A Curriculum for Physicians.
- 2008 Consultant for National Institute of Mental Health (NIMH) study (1R01MH079293-01A1; PI: D. Steinwachs). Improving Inpatient Psychiatric Payment: Cost and Quality Implications.
- 2010-2011 Substance Abuse and Mental Health Service Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), Division of Pharmacologic Therapies. Selected as nationally recognized expert in the treatment of opioid dependence, as regular faculty lecturer/leader in a series of nationwide trainings: MedEdTa: Opioid Treatment Program (OTP) Clinical Staff Education: Appropriate Use of Methadone in the OTP.
- 2014 Alkermes (pharmaceuticals). Participant, Opioid Treatment Program Advisory Board.

RECOGNITION

Awards, Honors

- 1984-1988 Maryland State Distinguished Scholar Award
- 1984-1988 University of Maryland Chancellor's Scholarship
- 1984-1988 Elected to membership in national collegiate honor societies, including:
Phi Beta Kappa
Alpha Lambda Delta
Phi Eta Sigma
Golden Key National Honor Society
- 1985 National Institutes of Health Outstanding Performance Rating and cash award
- 1988 Summa Cum Laude graduate, University of Maryland
- 1996 Wyeth-Ayerst Resident Reporter program: selected as Hopkins representative for program participation at the 1996 American Psychiatric Association Annual Meeting
- 1988 National Institute on Drug Abuse: Director's Travel Award to attend CPDD annual meeting
- 1996-1998 National Institutes of Health: National Research Service Award
- 2002 "Best Experienced Presenter Poster," Annual Meeting & Symposium of the American Academy of Addiction Psychiatry, Las Vegas, Nevada.
- 2007 Ernest Amory Codman Award Recipient: One of the Executive Committee members who, on behalf of Addiction Treatment Services at Hopkins Bayview, applied for and received this prestigious award from The Joint Commission.
- 2007 Elected to Fellow status in the American Psychiatric Association.
- 2013 "Top Manager," Johns Hopkins Medicine. In recognition of results on 2013 Gallup survey on employee engagement.
- 2015 "Clinical Collaboration and Teamwork Award for Clinical Excellence" nominee. Johns Hopkins Medicine's Office of Johns Hopkins Physicians.
- 2016 "Nyswander/Dole Award." Foremost award for extraordinary service in the opioid treatment field. "Award recipients have devoted themselves to improving the lives of patients in our treatment system. Dr. Vincent Dole and Dr. Marie Nyswander were the first recipients of this Award in 1983 acknowledging their groundbreaking work at Rockefeller University in the mid-1960s. Bestowed by the American Association for the Treatment of Opioid Dependence.

Invited Talks (*see also CME Instruction, Workshops, Seminars sections above for additional invited talks*)

JHMI/Regional:

- 11/ 2002 Grand Rounds presenter. *"Motivated Stepped Care in patients with opiate dependence: Efficacy across medications."* Johns Hopkins Hospital, Department of Psychiatry and Behavioral Sciences, Baltimore, Maryland.
- 7/2003 Invited Speaker. *"Substance abuse treatment is associated with lower health care cost in high cost Medicaid population."* Maryland HealthChoice Substance Abuse Workgroup, Catonsville, Maryland.
- 7/2003. Invited Speaker. *"The use of buprenorphine in primary care, psychiatric and substance abuse treatment settings."* Johns Hopkins HealthCare, Baltimore, Maryland.
- 11/2003 Workshop Leader. *"Methadone and buprenorphine: Long-term agonist treatment of opiate addiction."* Topics in Psychiatry, Fourth Annual Course, national program sponsored by the Johns Hopkins University School of Medicine, Baltimore, MD.
- 11/2003 Grand Rounds presenter. *"Substance use problems and health care costs among Maryland HealthChoice enrollees."* Johns Hopkins Hospital, Department of Psychiatry and Behavioral Sciences, Baltimore, Maryland.
- 3/2004 Clinical Grand Rounds presenter. *"Substance use problems and health care costs among Maryland HealthChoice enrollees."* National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland.
- 5/2005 "Understanding chemical dependency." Invited Community Action Speaker on chemical Independence Day commemoration, Baltimore Substance Abuse Services, Baltimore, Maryland.
- 11/2006 "Pain medications: Profiles and use in long term treatment." Invited Speaker - Distance Learning Seminar: Care Management of the Patient with Pain, presented as a statewide distance-learning seminar for Johns Hopkins HealthCare physicians and staff, Baltimore, Maryland.
- 12/2007 "Adaptive Stepped Care: a case for evidence-based use of intensive outpatient treatment." Invited speaker for Johns Hopkins HealthCare Administrative and Medical Leadership Committee.
- 3/2008 "Sticking with adherence" as a primary target of interventions for drug abuse." Grand Rounds presentation for the Johns Hopkins Hospital, Department of Psychiatry and Behavioral Sciences, Baltimore, Maryland.

- 7/2008 “Measured Paternalism and patient adherence.” Invited speaker at Behavioral Health Seminar - a joint meeting of somatic disease management and behavioral health care management teams. Johns Hopkins HealthCare, Glen Burnie, Maryland
- 9/2008 “Mood Disorders: Case Discussion and Clinical Pearls.” Invited speaker to quarterly Department of Care Management conference, Johns Hopkins HealthCare, LLC, Glen Burnie, Maryland.
- 1/2009 “Choice and Motivation in Addicted Populations: Should We Interfere?” Invited speaker at meeting of the Maryland Association of Chemical Dependency Nurses meeting, Baltimore, Maryland.
- 2/2009 “Choice and Motivation in Addicted Populations: Should We Interfere?” Invited speaker at meeting of the Clinical Ethics Committee of the Sheppard and Enoch Pratt Health System. Baltimore, Maryland.
- 5/2009 “Ethics of Choice and Motivation in Addicted Populations.” Psychiatric Grand Rounds presentation at Springfield Hospital Center. Sykesville, Maryland.
- 5/2009 “Paternalism and Structured Drug Abuse Treatment.” Invited speaker at the Program for Alcoholism and Other Drug Dependence. Baltimore, Maryland.
- 10/2009 “Integrated Substance Abuse and Somatic Care Management.” Gave testimony at Maryland State legislature workgroup (led by Del. Hammen) on improving coordination of substance abuse treatment. Annapolis, Maryland.
- 11/2009 “Drug Abuse as a Barrier to Health.” Internal Medicine Grand Rounds presentation at Johns Hopkins Bayview Medical Center. Baltimore, Maryland.
- 11/2009 “Primary Access to Care (PAC) Expansion.” Gave testimony to Maryland State legislature subcommittee (co-led by Del. Peter Hammen, Maryland Alcohol and Drug Abuse Administration, and Baltimore Substance Abuse Systems, Inc.) regarding the concerns and roles of Maryland hospitals in statewide substance abuse initiatives/proposals.
- 4/2010 “What’s Cost Got to Do with It?” Grand Rounds presentation for the Johns Hopkins Hospital, Department of Psychiatry and Behavioral Sciences. Baltimore, Maryland.
- 5/2010 “Buprenorphine Treatment for Opioid Dependence.” Invited speaker in seminar entitled, “Managing the Patient with Substance Abuse.” Johns Hopkins Medicine “Substance Abuse Day.”
- 10/2010 “Methadone Maintenance Treatment: Issues for Inpatient Providers.” Invited speaker. Educational seminar, Johns Hopkins Hospital Departments of Social Work and Psychiatry. Baltimore, Maryland.
- 11/2010 “Hospital Inpatients with Substance Use Disorder.” Grand Rounds presentation for the Johns Hopkins Hospital, Department of Pharmacy. Baltimore, Maryland.
- 1/2011 “Treatment Options for the Patient with Opioid Dependence.” Grand Rounds presentation at Springfield Hospital Center. Sykesville, Maryland.
- 10/2011 “Systems in Addiction Treatment.” Grand Rounds presentation for the Johns Hopkins Hospital, Department of Psychiatry and Behavioral Sciences. Baltimore, Maryland.
- 4/2012 “Substance Use Disorders.” Invited speaker and seminar leader. Divisional meeting. Baltimore County Department of Social Services. Towson, Maryland.
- 5/2012 “Mood Disorders.” Invited speaker and seminar leader. Half-day training sponsored by the Baltimore City Substance Abuse Directorate. Baltimore, Maryland.
- 5/2013 “Care of the Hospitalized Patient on Opioid Maintenance Therapies.” Invited speaker at JHM Nursing: Treating Patients with Substance Use Disorders. Johns Hopkins Hospital. Baltimore, Maryland.
- 3/2014 “Optimizing Addiction Treatment: Must We All Become Megamalls?” Grand Rounds presentation for the Johns Hopkins Hospital, Department of Psychiatry and Behavioral Sciences. Baltimore, Maryland.
- 9/2015 “*Coordinated Buprenorphine Treatment: Supporting Maryland’s Prescribers, Expanding the Continuum of Care.*” Invited speaker. Maryland Society of Addiction Medicine – Annual Meeting 2015. Baltimore, Maryland.
- 9/2015 “Comprehensive and Innovative Treatment in Opioid Treatment Programs.” Invited speaker. Behavioral Health Systems Baltimore - Methadone Roundtable. Baltimore, MD
- 10/2015 “Linking Opioid Treatment Programs and Office-based Buprenorphine Providers.” Invited Speaker. Maryland Department of Health and Mental Hygiene. “Continuing Medical Education (CME) and Pharmacy Continuing Education (CE) Seminar. Updates in Treatment Strategies for Complicated Disease States: Substance Abuse and Hepatitis C.” Baltimore, Maryland.
- 11/2017 “The Opioid Epidemic.” Invited faculty for Johns Hopkins Medicine annual event, “A Woman's Journey.” Baltimore, Maryland.
- 1/2018 “The Opioid Epidemic (A Mother’s Journey)” Invited speaker for public event at The Saint Paul’s School for Girls, part of event entitled “Johns Hopkins Medicine – Health and Wellness Journey.” Baltimore, Maryland.

National:

- 12/2004 “An adaptive treatment approach to adjust treatment intensity and motivate patient attendance.” Invited Speaker at conference sponsored by the Ohio Department of Alcohol and Drug Addiction Services in collaboration with the Center for Substance Abuse Treatment entitled, Medication Assisted Treatment: Blending Abstinence-Based Care with Pharmacological Support, Columbus, Ohio.
- 5/2006 “Structuring the Integration of Services for Medicaid Recipients with Chronic Illness and Psychiatric and/or Substance Abuse Problems.” Speaker at Center for Health Care Strategies: Medicaid Value Program: Health Supports for Consumers with Chronic Conditions, Philadelphia, Pennsylvania.
- 3/2009 “Stepped Care: An Adaptive Treatment Approach.” The Joint Commission. Invited Co-leader for national audioconference on Best Practice Models for Opioid Treatment Programs.
- 9/2014 “Management of Benzodiazepine Use in Opioid Treatment Programs.” Invited guest presenter. National Association of State Alcohol/Drug Abuse Directors - Opioid Treatment Network Topic National Call.
- 8/2015 “Innovative Practices in Medication Assisted Treatment and Primary Care Coordination.” Invited national webinar speaker. Webinar sponsored by The White House Office of National Drug Control Policy and the U. S. Substance Abuse and Mental Health Services Administration.
<https://www.youtube.com/watch?v=-4Bm3vE7DH0>
- 6/2016 “Improving MAT Access and Quality Through Collaborative Care: The CoOP Model.” Invited national webinar presenter. American Psychiatric Association sponsored national webinar for SAMHSA’s Provider Clinical Support System (PCSS). Online.
- 6/2016 “Medication Assisted Treatment: Opportunities for Community Centers.” Invited speaker. Invited by the National Council for Behavioral Health, to speak at the Texas Council of Community Centers - 31st Annual Conference. San Antonio, TX.
- 2/2017 Led national teleconference discussion (all states represented) on “Buprenorphine Expansion.” Joint National Treatment Network - Opioid Treatment Network (NTN - OTN), in combination with SAMHSA Project Officers and SAMHSA’s Department of Pharmacologic staff. Monthly “Topic call”.
- 8/2017 “CoOP: Integrative Opioid MAT to Improve Treatment Capacity, Access and Quality.” Webinar for University of Nevada, Reno. Center for the Application of Substance Abuse Technologies/CASAT. Reno, Nevada (remotely).
- 9/2017 “Expansion of Medication Treatments for Opioid Use Disorder.” Featured speaker, SAMHSA national conference call with state and federal representatives from behavioral health agencies, State Medicaid officers, U.S. Centers for Disease Control, SAMHSA leadership, on 9/7/2017
- 9/2017 “*America’s Opioid Epidemic: Search for Solutions.*” Speaker Panel, audience being field leaders, lawmakers, government officials, researchers. The Hill national event, in Washington D.C. and televised nationally. Co-panalists include NIDA Director Nora Volkow, Senator Rob Portman and others listed at:
<http://thehill.com/event/345703-america-s-opioid-epidemic-search-for-solutions>
- 12/2017 “CoOP: A ‘Plug & Play’ Hub & Spoke Model to Increase MAT Access and Quality.” Speaker, Expert Panelist, audience state and federal government policymakers, behavioral health agency representatives. SAMHSA Region 3 meeting: Expanding Medication Assisted Treatment Partnership Summit. Washington, D.C.
- 4/2018 “Care Coordination 101.” Webinar speaker for first of a SAMHSA-sponsored series entitled “Innovative and Integrated Treatment Models: Increasing Impact of Opioid Treatment Programs through Care Coordination.” Audience: mixed clinicians and policymakers. Presentation streaming available at:
https://www.youtube.com/watch?v=P66eqA_9QBg&feature=youtu.be
- 6/2018 “The Changing World of Addictions: Social workers poised to be an integral part of the solution.” Opening speaker at SAMHSA-sponsored summit entitled “SAMHSA Region III/CSWE Addiction Education Summit.” Summit purpose was to identify how U.S. schools of social work can address the increasing need for social workers with in addictive disorders.

International:

- 3/2018 “The U.S. Experience (in treatment of opioid use disorder).” Invited as panelist representing the U.S. regarding addiction treatment, at this Canadian forum, telecast nationally, entitled “Pillars of Change: Priorities for Addressing the Opioid Crisis.” Meeting joint sponsored by the Embassy of the United States (Ottawa, Canada), and the Canadian Centre on Substance Use and Addiction. Audience: policymakers, law enforcement leadership, governmental officials, public health researchers/officials. Ottawa, Canada.

OTHER PROFESSIONAL ACCOMPLISHMENTS

Posters (limited to first-author/presenter)

- 6/1997 **Stoller, K.B.**, Brooner, R.K., King, V.L., Kidorf, M.S. Comparison of Opioid Abusers with Independent Versus Substance-Induced Major Depression. Presented at the Annual Scientific Meeting of the College on Problems of Drug Dependence, Nashville, Tennessee.
- 3/1998 **Stoller, K.B.**, Stitzer, M.L., Brooner, R.K., King, V.L., Kidorf, M.S. Smoking Cessation Program in an Opioid Substitution Clinic. Presented at Society for Research on Nicotine and Tobacco, New Orleans, Louisiana.
- 6/1998 **Stoller, K.B.**, Strain, E.C., Bigelow, G.E. Evaluation of Opioid Antagonist Activity in Humans: Effect of Buprenorphine/Naloxone. Presented at the Annual Scientific Meeting of the College for Problems of Drug Dependence, Scottsdale, Arizona.
- 6/1999 **Stoller, K.B.**, Brooner, R.K., Kidorf, M.S., King, V.L., Carter, J.A. Characterization of opioid substitution patients referred from needle exchange. Presented at the Annual Scientific Meeting of the College on Problems of Drug Dependence, Acapulco, Mexico.
- 6/2000 **Stoller, K.B.**, Carter, J.A., King, V.L., Kidorf, M.S., Brooner, R.K. Behaviorally contingent pharmacotherapy in the treatment of opioid dependent patients on LAAM. Presented at the Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, Puerto Rico.
- 6/2001 **Stoller, K.**, Kidorf, M., King, V., Carter, J., Brooner, R. Characteristics of drug treatment patients with versus without medical assistance. Presented at the Annual Scientific Meeting of the College on Problems of Drug Dependence, Scottsdale, Arizona.
- 12/2002 **Stoller, K.B.**, Carter, J.A., King, V.L., Kidorf, M.S., Brooner, R.K. Early Treatment Response to a "Motivated Stepped Care" Approach Using Methadone or LAAM. Presented at the Annual Meeting & Symposium of the American Academy of Addiction Psychiatry, Las Vegas, Nevada, Awarded "Best Experienced Presenter Poster."
- 12/2002 Brooner, R.K., Kidorf, M.S., King, V.L., **Stoller, K.B. (Stoller presented)**. Integrating Pharmacotherapy with Counseling and Behavioral Reinforcement to Improve Treatment Outcome: "Motivated Stepped Care". Presented at the Annual Meeting & Symposium of the American Academy of Addiction Psychiatry, Las Vegas, Nevada.
- 6/2003 **Stoller, K.B.**, Brooner, R.K., Brittingham, L.W., Demarest, C.M., Ferrugia, E., Dunbar, L.J., Schwartz, J.M., Schmidt, C.W. Substance Abuse Treatment is Associated with Lower Health Care Costs. Presented at the Annual Scientific Meeting of the College on Problems of Drug Dependence, Bal Harbour, Florida.
- 6/2004 **Stoller, K.B.**, Brooner, R.K., Demarest, C.M., Dunbar, L.J., Ferrugia, E., Riley, M.M., Strain, E.C., Schmidt, C.W. Substance abuse treatment is associated with lower health-care costs in substance abusing Medicaid managed-care enrollees. Presented at the Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, Puerto Rico.
- 10/2004 **Stoller, K.B.**, Russell, L. Operationalizing integrated managed care for a Medicaid population with substance abuse and high medical expenses: moving from silos to roundtables. Presented at Addiction Health Services Research conference, Philadelphia, Pennsylvania.
- 10/2004 **Stoller, K.B.**, Brooner, R.K., Dunbar, L.J., Fagan, P.J., Ferrugia, E., Schmidt, C.W. Substance abuse treatment remains associated with lower health care costs in Medicaid managed care organization enrollees. Presented at Addiction Health Services Research conference, Philadelphia, Pennsylvania.
- 6/2005 **Stoller, K.B.**, Kidorf, M.S., King, V.L., Neufeld, K., Peirce, J., Brooner, R.K. Incorporating family and friends to build support networks among patients on methadone. Presented at the Annual Scientific Meeting of the College on Problems of Drug Dependence, Orlando, Florida.
- 8/2005 **Stoller, K.B.** Incorporating family and friends to build support networks among patients on methadone. Presented at NIDA Mentored K Awards Meeting: Making the Transition to Independent Drug Abuse Scientist, Bethesda, Maryland.
- 6/2006 **Stoller, K.B.**, Alexandre, P., Strain, E., Kidorf, M.1; King, V., Brooner, R. "Behavioral contingencies can reduce the costs of counseling services in adaptive stepped care treatment approaches". Presented at the Annual Scientific Meeting of the College for Problems in Drug Dependence, Scottsdale, Arizona.
- 6/2006 **Stoller, K.B.**, Fagan, P., Sylvia, M., Griswold, M.E., Alexandre, P., Dunbar, L.J., Brooner, R.K. Lower health care costs in Medicaid managed care organization enrollees treated for substance abuse: Incentive for taking action. Presented at the AcademyHealth Annual Research Meeting, Seattle, Washington.
- 6/2007 **Stoller, K.**, Fagan, P., Dunbar, L., Sylvia, M., Griswold, M., Hawkins, M., Brooner, R. Integrative care management for substance abusing Medicaid recipients. Presentation at College for Problems of Drug Dependence Annual Scientific Meeting, Quebec City, Quebec.
- 6/2008 **Stoller, K.**, Schuster, A., Tompkins D.A., Fagan, P., Dunbar, L. Schmidt, C, Brooner, R. Consistent use of methadone maintenance is associated with lower cost to the managed care organization. Presentation at College for Problems of Drug Dependence Annual Scientific Meeting, San Juan, Puerto Rico.

12/2015

Stoller, K., Louie, C., Stephens, M. Title: “Increasing Office-Based Buprenorphine Availability and Efficacy through Coordination with Opioid Treatment Programs.” Presentation at 27TH Annual Meeting and Scientific Symposium of the American Academy of Addiction Psychiatry, Huntington Beach, California.